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ABSTRACT OF DISSERTATION  
 
 
 
 
TRANSLATIONAL REGULATORY MECHANISMS OF  
THE RAT AND HUMAN MULTIDRUG RESISTANCE PROTEIN 2 
 
Multidrug resistance protein 2 (MRP2) is the second member the C 
subfamily in the superfamily of adenosine triphosphate (ATP)-binding cassette 
(ABC) efflux transporters. MRP2 is a critical player for generation of bile acid-
independent bile flow and biliary excretion of glutathione, glucuronate and sulfate 
conjugates of endo- and xenobiotics. Dysfunctional expression of MRP2 is 
associated with Dubin-Johnson Syndrome.  
 
Pathological and physiological states or xenobiotics change the MRP2 
expression level. Under some conditions, expression of the human MRP2 and rat 
Mrp2 proteins are regulated at the translation level. There are several 
transcription initiation sites in MRP2/Mrp2 gene. The 5’ untranslated regions 
(5’UTRs) of MRP2/Mrp2 contains multiple translation start codons. The focus of 
this study, therefore, was investigation of the translational regulatory 
mechanisms mediated by the upstream open reading frames (uORF) of 
MRP2/Mrp2. 
 
Using in vitro translation assays and transient cotransfection assays in 
HepG2 cells, we showed that the rat uORF1 starting at position -109 (relative to 
the ATG of Mrp2) and the human uORF2 starting at position -105 (relative to the 
ATG of MRP2) are two major cis-acting inhibitors of translation among the rat 
and human multiple uORFs, respectively. Translational regulation mediated by 
the uORFs in the rat Mrp2 mRNA is a combined effect of the leaky scanning 
model and the reinitiation model, and also results from interaction of the multiple 
uORFs. In addition, by Ribonuclease Protection Assays (RPA), we detected 
multiple transcription initiation sites of MRP2/Mrp2 gene in tissues. We also 
found that the relative abundance of the rat Mrp2 mRNA isoforms with different 
5’UTRs differed in the rat liver, kidney, jejunum, ileum, placenta, and lung. This is 
the first study on the translational regulatory mechanisms of the MRP2/Mrp2 
gene.  
 
KEYWORDS: Multidrug resistance protein 2 (MRP2), Translational regulation, 
 
5’ Untranslated region (5’UTR), Upstream open reading frame (uORF), 
Transcription initiation sites.  
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CHAPTER ONE 
INTRODUCTION 
Multidrug resistance protein 2 (MRP2, also ABCC2) is the second member 
identified of the 12 transporters of the C subfamily in the superfamily of 
adenosine triphosphate (ATP)-binding cassette (ABC) efflux transporters [1]. It is 
also termed the canalicular multispecific organic anion transporter (cMOAT) and 
canalicular multidrug resistance protein (cMRP2) [2, 3]. Forty eight ABC 
transporters have been identified in human beings, and grouped into seven 
subfamilies designated from A to G, based on the amino acid sequence similarity 
and phylogeny. Human MRP2 and rat Mrp2 are integral plasma membrane 
proteins and are exclusively expressed in the apical membrane of polarized cells 
of human and rat liver [2, 4, 5], kidney proximal tubules [6, 7], small intestine [8-
10], human colon [9, 11], gallbladder [12], bronchi [9, 11], and placenta [13, 14]. 
The human hereditary disorder, Dubin-Johnson Syndrome, is characterized by 
conjugated hyperbilirubinemia and is associated with the absence of expression 
of the functional MRP2 in the canalicular membrane of hepatocytes [2, 15]. 
Expression of Mrp2 is absent in the natural animal models of Dubin-Johnson 
Syndrome: the Groningen yellow/transport deficient Wistar rat (GY/TR-) and the 
Eisai hyperbilirubinemic Sprague-Dawley rat (EHBR). This is due to 1bp deletion 
in the Mrp2 gene that results in introduction of a premature stop codon in the 
mRNA and subsequent degradation of the transcript [4, 16, 17]. Like MRP1, 
MRP2/Mrp2 are predicted by computational analysis to contain three membrane-
spanning domains (MSD0, MSD1, and MSD2) consisting of 17 transmembrane 
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helices. There are two highly conserved nucleotide-binding domains, NBD1 and 
NBD2, following MSD1 and MSD2, respectively [4, 18, 19]. Further, the 
extracellular localization of the amino terminus of human MRP2 is confirmed by 
immunofluorescence studies [19, 20].  
Generation of bile flow is dependent on active transport of osmotically active 
solutes across the canalicular membrane of hepatocytes into the canaliculi. The 
two major solute contributors to bile are bile salts and glutathione (GSH). 
Because of its localization and substrate specificity, MRP2/Mrp2 is considered to 
be a critical player for generation of bile acid-independent bile flow. It is 
exclusively present on the canalicular membrane of hepatocytes, and excretes 
GSH and conjugates of glutathione, glucuronide, and sulfate into bile. In addition 
to the conjugated bile acids, substrates of MRP2/Mrp2 include organic anions of 
endogenous and exogenous origin, such as leukotriene C4, 2,4 dinitrophenyle-S-
glutathione (DNP-SG), and estradiol-17β-D-glucuronide (E217G). 
 
Regulation of MRP2/Mrp2 expression 
Expression of MRP2/Mrp2 is also tissue-specific and regulated by drug 
treatments and diseases. Regulation of MRP2/Mrp2 expression occurs at all 
levels: transcription, post-transcription, translation, and post-translation (e.g., 
endocytic retrieval from the apical membrane).  
Transcriptional regulation. Kauffmann et. al sequenced the 5’-flanking region 
of the rat Mrp2 gene (-1073 to -14 bp with respect to the translation start site). 
They characterized two regions that mediate constitutive expression of Mrp2: 17 
2 
bp at position -317 to -290 and 37 bp at position -250 to -214. The first region 
contains an inverted CCAAT element, which is the core sequence of the Y-Box. 
The second region is a GC-Box, which is a binding site for the transcription 
factor, specificity protein (Sp1). The regulatory mechanism of constitutive 
expression of the Mrp2 gene is very similar to MRP1 or members of the Mdr1 
family. Other putative binding sites for transcription factors found by 
computational analysis are several glucocorticoid responsive elements (GREs) 
and peroxisome proliferators responsive elements (PPREs), as well as activator 
protein 1 (AP1), C-repeat binding factor (CBF), CCAAT-enhancer binding protein 
α (C/EBPα), enhancer factor I A (EFIA), hepatic nuclear factor 1 (HNF1), c-Myb, 
polyomavirus enhancer A binding protein-3 (PEA3), and Sp1 [21]. 
The 2.7 kb 5’-flanking region of the human MRP2 gene in a human placental 
genomic library has also been sequenced [22]. A positive regulatory element is 
localized in the -431 to -258 bp region that contains the transcription factor 
binding site of C/EBPβ. Comparison of the 5’-flanking regions between human 
and rat shows 51% nucleotide sequence identity. Both contain two elements, 
hepatic nuclear factor 1 (HNF1) and upstream stimulatory factor (USF)-like 
element, which are predicted by computational programs [22]. 
Expression of the Mrp2 gene in rat hepatocytes is inducible by a variety of 
carcinogenic and chemotherapeutic agents, such as 2-acetylaminofluorene (2-
AAF), cisplatin, phenobarbital, ethiny estradiol and cyclohemixide [21]. The 
mRNA levels of MRP2/Mrp2 are up-regulated in human and rat hepatoma cell 
lines (HepG2 and FAO cells, respectively), following treatment of agonists of the 
3 
farnesoid X-activated receptor (FXR), the pregnane X receptor (PXR), and the 
constitutive androstane receptor (CAR). In the rat 5’ flanking region of the Mrp2 
gene, an unusual 26 bp sequence at position -401 to -376 is identified to contain 
two copies of the AGTTCA hexad organized as an ER-8. PXR, CAR or FXR bind 
to ER-8 as a heterodimer with the retinoid X receptor α (RXRα) [23]. 
Expression of both Mrp2 mRNA and protein is reduced in the cholestatic rat 
liver induced by bile duct ligation or endotoxin [24-26]. This down-regulation 
induced by endotoxin is partly due to up-regulated expression of the 
inflammatory cytokine interleukin-1β (IL-1β). IL-1β is reported to down-regulate 
the heterodimer of retinoic acid receptor α (RARα)/RXRα, resulting in down-
regulation of Mrp2 promoter activity [27, 28]. In HepG2 cells, IL-1β represses 
expression of the MRP2 gene because it inactivates binding of the interferon 
regulatory factor (IRF3) to the interferon stimulatory response element (ISRE) on 
the MRP2 promoter [29]. 
Endocytic retrieval from the apical membrane. Transporter function is also 
regulated at the post-translation level due to trafficking of MRP2/Mrp2 protein 
between the canalicular membrane and a peri-canalicular pool of vesicles. Mrp2 
is retrieved into intracellular structures following isolation and culture of rat 
hepatocytes, and resorted into the apical membrane in a time-dependent fashion, 
which is consistent with changes in transport activity [30]. The trafficking of Mrp2 
protein and changes in transport activity are confirmed in sandwich-cultured rat 
hepatocytes [31].  
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This trafficking is inducible. Phalloidin, a potent mushroom hepatotoxin and 
cholestatic agent, induces significant internlization of Mrp2 along with other 
canalicular proteins. The induced retrieval coincides with decreased bile flow and 
decreased biliary excretion of Leukotriene (LTC4), an Mrp2 substrate [32]. 
Treatment of rats with lipopolysaccharide (LPS) causes endocytic retrieval of 
Mrp2 along with cholestasis [33, 34]. Finally, a single dose of estradiol-17β-D-
glucuronide (E217G) induces a potent dose-dependent and reversible inhibition 
of bile flow in the rat. This coincides with a rapid endocytic internalization of Mrp2 
and with subsequent spontaneous exocytic insertion of Mrp2 into the apical 
membrane [35].  
Retrieval of the hepatic MRP2 in human beings is also reported in several 
studies. Percutaneous transhepatic biliary drainage (PTBD) is a treatment to 
reduce hyperbilirubinemia in patients with obstructive cholestasis. In the liver 
biopsy specimens of cholestatic patients who were poorly drained, fuzzy 
immunostaining of MRP2, which indicates internalization from the canalicular 
membrane, is observed, in contrast to the linear and intense immunostaining 
outlining the canalicular membrane domain in the liver of control subjects, which 
indicates canalicular membrane localization. This correlates with the impaired 
bilirubin conjugate and bile acid secretion [36]. Moreover, hepatic MRP2 
immunostaining is broadened and irregular in non-icteric primary biliary cirrhosis 
(PBC) stage III, while a thin and clear line on the canalicular membrane is seen 
in controls. This indicates re-distribution of MRP2 localization from the canalicular 
membrane into intracellular structures of the hepatocytes in PBC-III patients [37]. 
5 
Many studies have addressed the mechanisms of altered localization of 
MRP2/Mrp2 in the cholestatic liver. Cyclic AMP stimulates microtubule-
dependent transport of vesicles [38]. E217G induces endocytic retrieval of 
hepatic Mrp2 in rats. But treatment of dibutyryl-cyclic AMP (DBcAMP) preceding 
E217G attenuates this retrieval and accelerates re-distribution of Mrp2 into the 
canalicular membrane along with restoration of bile flow. In contrast, prior 
administration of colchicine that disrupts microtubules, blocks the actions of 
DBcAMP [39]. The data indicate involvement of microtubule in Mrp2 trafficking. 
Radixin is a cross-linker between actin filaments and plasma membrane 
proteins. Radixin knockout mice show a loss of Mrp2 from the canalicular 
membrane and develop conjugated hyperbilirubinemia [40]. In the rat models of 
intrahepatic and extrahepatic cholestasis, along with endocytic retrieval of 
hepatic Mrp2, the colocalization of Mrp2 and radixin is disturbed. Phosphorylated 
radixin shown by fluorescence markedly decreases in both intra- and 
extrahepatic cholestasis in rats, indicating an important role of the reduced 
phosphorylated radixin in the endocytic retrieval of Mrp2 in cholestasis [41]. That 
is, inactivation of radixin may weaken anchorage of Mrp2 in the canalicular 
membrane [41]. Disturbed colocalization of MRP2 and radixin as well as 
endocytic retrieval of MRP2 is detected by immunofluorescence in various 
human cholestatic liver diseases [42]. The mechanisms of disturbed interaction 
between radixin and Mrp2/MRP2 in cholestasis are still unclear. But radixin is 
essentially involved in maintaining the canalicular localization of Mrp2, since 
6 
down-regulated radixin by iRNA induces dissociation of Mrp2 from the canalicular 
membrane and down-regulates Mrp2 function [43]. 
Translational regulation. Under some conditions, expression of MRP2/Mrp2 
undergoes translational regulation. Hepatic Mrp2 protein is expressed 50% less 
in the pregnant rat liver than in the control rat, even though the mRNA level is 
unchanged [44-46]. Ethinylestradiol (EE2) decreases the Mrp2 protein markedly 
in the rat liver, but the mRNA does not change. Moreover, treatment with EE2 
does not affect the relative abundance of the three Mrp2 mRNA transcripts that 
contain different 3’-untranslated regions (UTR) [26]. In cultured H4IIE cells, a rat 
hepatoma cell line, EE2 treatment also caused a significant decrease in the Mrp2 
protein in contrast to an increase in the Mrp2 mRNA level [21]. Conversely, 
hepatic Mrp2 protein in rats treated with pregnenolone 16α-carbonitrile (PCN) 
increases 2-3 fold, while the mRNA level is not changed [46, 47]. Together, the 
data show a poor association between the Mrp2 protein and mRNA, indicating 
that under these conditions and treatments, Mrp2 protein expression is under 
post-transcriptional regulation.  
To investigate the mechanism of post-transcriptional regulation of Mrp2 
expression, our lab previously analyzed Mrp2 synthesis and degradation in 19- 
and 20-day pregnant rats, and PCN-treated rats as well as in control female rats. 
[35S]cysteine/methionine and [14C]NaHCO3  were administered into rats to study 
the rate of synthesis and the degradation half-life of Mrp2 protein, respectively. 
The measured degradation half-lives of 14C-labeled Mrp2 are not significantly 
different in control, pregnant, and PCN-treated rats (27, 36, and 22 h, 
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respectively). However, the rate of incorporation of 35S into hepatic Mrp2 is the 
highest in the PCN-treated rats relative to that in the control rats. The initial rate 
of synthesis in the pregnant rats could not be obtained because of the very low 
level of incorporation of 35S into Mrp2 protein. Additionally, polysomal distribution 
analysis of hepatic Mrp2 mRNA in the control, pregnant, and PCN-treated female 
rats showed that 1) more Mrp2 mRNA transcripts are associated with polysomes 
in the PCN treated rats; 2) more Mrp2 mRNA transcripts are associated with a 
single ribosome in the pregnant rats. In both cases, no major change is observed 
in relative distribution of the Mrp2 mRNA 5’UTRs. Therefore, post-transcriptional 
regulation in the control, pregnant, and PCN-treated rats occurs not through 
degradation of Mrp2 protein, but through the rate of Mrp2 protein synthesis, 
indicating translational regulation of rat Mrp2 protein [46].  
Moreover, along the small intestine in rats, expression of Mrp2 protein is 
maximal in the duodenum and jejunum, and decreases gradually to 5% of the 
maximum in the terminal ileum, whereas there is no significant decrease of  the 
Mrp2 mRNA level in the terminal ileum compared to that in the 
duodenum/jejunum [48]. 
Several studies show that expression of human hepatic MRP2 protein also 
undergoes translational regulation. No changes in the MRP2 mRNA levels are 
observed in patients with icteric inflammatory cholestasis, but the MRP2 protein 
levels are markedly reduced as shown by immunolabeling [49]. In one 
experimental model, cholestasis is induced by enodotoxin or lipopolysaccharide 
(LPS). The acute phase response of liver to LPS treatment is initiated by 
8 
producing pro-inflammatory cytokines such as TNF-α, IL-1 β, and IL-6, as well as 
anti-inflammatory cytokines such as IL-10 [50]. LPS treatment of human liver 
slices impairs expression of MRP2 protein, with the mRNA level unchanged and 
no intracellular vesicles containing MRP2 observed by immunofluorescence [51]. 
Finally, HepG2 cells treated with TNF-α or IL-1β showed no significant changes 
in the MRP2 mRNA level [52]. There are no studies on the mechanisms of 
translational regulation of human MRP2 to date  
 
Translational regulatory mechanisms  
There are many factors controlling translation of mRNA in eukaryotic cells, 
such as microRNA, mRNA binding proteins, translation initiation factors, and 
intrinsic characteristics of mRNA (5’ and 3’ untranslated regions (UTRs), 
secondary structures, etc.). Here, we will discuss the 5’UTR as a regulatory 
factor in translation. 
5’ Untranslated region mediated translational regulation. The 40S ribosomal 
subunit binds with Met-tRNA/eIF2-GTP and other eukaryotic initiation factors 
(eIFs), and thus the 43S pre-initiation complex is formed (Figure 1.1.). According 
to the scanning model of translation (shown in Figure 1.1.), the 43S complex 
attaches to the 5’ 7-methylguanosine (5’ m7G) capped site of an mRNA, and 
recruits more eIFs (eIF4B, eIF4F, etc.), generating the 48S complex. The 48S 
complex migrates linearly along the mRNA in the 5’ → 3’ direction until it 
encounters the first translation initiation codon (ATG). Once the first AUG is base 
paired with Met-tRNA in an optimal context, the 48S complex stops and 
9 
translation initiation factors are released from the initiation complex. The 60S 
ribosomal subunit joins the 40S subunit. Thus translation is initiated at the first 
AUG and the proceeds with the elongation stage [53]. This is also called the first-
AUG rule. The regulators of translation initiation include: 1) 7-methylguanosine 
(m7G) capped structure at the 5’ end. All cellular and most viral mRNAs have 5’ 
m7G capped ends [54]. Interaction between the 5’ m7G cap and eIF4E strongly 
promotes ribosome binding with mRNA [55, 56], and translational efficiency of an 
mRNA without a 5’ m7G cap is reduced more than 10-fold in in vivo experiments. 
2) The context sequence flanking the AUG. Kozak et. al [53] found the optimal 
context for translation initiation in eukaryotic cells: GCCRCCatgG (named Kozak 
Motif). The critical nucleotides in the Kozak Motif are the purine in position -3 and 
the G in position +4 (where the A in AUG is numbered +1). Mutation of the 
nucleotides at these two positions strongly reduces translational efficiency. 3) 
The length and the secondary structure of the 5’ leading region prior to the first 
AUG. Usually, a longer 5’ leader is thought to slow down translation initiation 
since the scanning 40S subunit needs more time to migrate from the end to the 
first AUG. But one report showed that the distance of >1000 nt from the 5’ end to 
the first AUG does not reduce the translational efficiency [57]. Kozak argues that 
the length of 5’-leader prior to the first AUG is irrelevant in terms of translation 
initiation [58]. However, a long 5’-leader sequence usually contains a secondary 
structure. A stable stem-loop secondary structure formed by base pairing in the 
leader sequence is inhibitory by blocking access of the 40S subunit to the AUG 
[59-61].  
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The 5’ leader sequence prior to the ATG (we use cDNA codon, ATG, instead 
of AUG in following text) of the main open reading frame (ORF) is commonly 
called the 5’ untranslated region (5’UTR). Here, we call the ATGs present in the 
5’UTR as upstream ATGs. It is estimated that at least 10% of human 5’UTRs 
contain upstream ATGs. According to the first ATG rule, the 48S subunits 
recognize the first ATG by base pairing while scanning. Downstream ATGs only 
can be recognized through two mechanisms. First is context-dependent leaky 
scanning, in which the 48S subunits bypass the first ATG present in an 
unfavorable context and proceed to advance to the downstream ATGs. Second 
is reinitiation following translation of upstream open reading frames (uORFs). 
The translational machineries efficiently recognize the upstream ATGs and 
translate the uORFs. But after finishing translation of the uORFs, the translational 
machineries do not dissociate from mRNA strands, but remain bound on the 
mRNA strands and continue scanning until encountering the next ATG where 
they initiate translation again. The best studied example of uORFs as 
translational regulators is the general control protein GCN4 gene, which 
demonstrates the orchestrated effect of multiple uORFs on translational 
regulation.  
The GCN4 [62] protein of the yeast Saccharomyces cerevisiae is a 
transcriptional activator of amino acid biosynthetic genes. Translation of the 
GCN4 mRNA is derepressed in amino acid-deprived cells. The derepression is 
the orchestrated effect of the four short uORFs (named uORF1-4) in GCN4 
mRNA and phosphorylation of eukaryotic initiation factor 2 (eIF-2). These four 
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uORFs determine where initiation, re-initiation, and leaky scanning of the 
translation complex occur from the capped end to the GCN4 ATG. In an amino 
acid-rich medium, ribosomes translate uORF1 and reinitiate primarily at uORF4, 
but are unable to access the GCN4 ATG. In amino acid-deprived cells, 
ribosomes still translate uORF1, but bypass uORF2 through uORF4 and 
reinitiate at the GCN4 ATG instead. The fact that the GCN4 synthesis is due to 
reinitiation at the GCN4 ATG following translating uORF1 has been 
demonstrated by two experiments. First, when uORF1 is elongated to overlap the 
encoding region of GCN4, GCN4 expression is abolished. Second, GCN4 
expression is reduced as uORF1 is moved progressively closer to the GCN4 
ATG, which is consonant with Kozak’s finding that reinitiation efficiency at the 
downstream ATG is reduced as the distance from the upstream ATG to the 
downstream ATG is gradually decreased [63]. Therefore, uORF4 and the GCN4 
ORF are competitors for the scanning ribosomes after translating uORF1. The 
level of the active form of eIF2 determines whether uORF4 or GCN4 captures the 
ribosomes more efficiently. In conclusion, GCN4 expression in derepression 
conditions is a result of two mechanisms: reinitiation after uORF1 translation and 
leaking scanning of uORF2-4.  
uORF-encoded peptide mediated translational regulation. In addition to the 
mechanisms of leaking scanning and reinitiation, a mechanism by which uORFs 
modulate translation depends on the properties of the peptide encoded by the 
uORFs. Missense mutations in the uORFs interfere with its control function. In 
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this mechanism, translational regulation is dependent on the amino acid 
sequence of the encoded peptide by a uORF [64].  
A uORF-encoded peptide can cause ribosome stalling. The arginine 
attenuator peptide (AAP) is encoded by an evolutionarily conserved uORF. This 
uORF is present in the 5’UTRs of both S. cerevisiae CPA1 and N. crassa arg-2 
mRNAs. In the presence of arginine, expression of both CPA1 and arg-2 mRNA 
is repressed. The investigation of the underlying mechanism shows that the 
scanning ribosomes translate the uORF of AAP first and the newly synthesized 
AAP then causes the ribosomes to stall at the termination codon. As a result, the 
ribosomes are blocked from reaching the main ORF of CPA1 and arg-2 mRNAs. 
In contrast, in the absence of arginine, the AAP uORFs are bypassed by most 
scanning ribosomes (leaking scanning), and the main ORFs are translated. 
Therefore, a uORF regulates translation of a downstream cistron not only 
through reinitiation, but also through stalling ribosomes [65, 66].  
The ribosome stalling model resembles that exerted by the 22-codon uORF2 
of human cytomegalovirus gpUL4 and the 6-codon uORF of S-
adenosylmethionine decarboxylase (AdoMetDC). Mutants of these uORFs 
abolish the ribosome stalling, resulting in failure to inhibit translation of the 
downstream main ORF. The inhibitory effect of the uORFs on the gpUL4 and 
AdoMethDC mRNAs is eliminated when the terminal codons of the uORFs are 
removed. This suggests that the nascent peptides translated from the uORFs 
interfere with the translation termination reaction. Further studies showed that the 
affected step occurs prior to peptidyl-tRNA hydrolysis [67-70]. Raney and Morris 
13 
experimentally detected an intermediate in the termination process of translation 
of the uORF, the complete nascent peptide linked to the tRNA. They also show 
that association of this complex with the ribosome is regulated by levels of 
polyamine.  
Several studies have successfully detected uORF-encoded peptides in vitro 
and in vivo. The glucocorticoid receptor (GR) mRNA contains five uORFs 
(uORF1-5). Among them, only the peptide encoded by uORF2 is detected by 
immunoblotting analysis in the in vitro translation reaction and in liver cells. 
Moreover, disruption of uORF2 abolishes synthesis of this peptide and also GR, 
suggesting that the peptide may be involved in translation of GR [71]. The 
hexapeptide (sequence MAGDIS) encoded by the uORF of AdoMetDC is also 
detected as a product of in vitro translation reaction by HPLC, following a series 
of purification steps [72]. In addition, four novel small uORF-encoded peptide 
(<100 amino acids in length) were recently detected using high-resolution 
nanoflow liquid chromatography coupled with electrospray inonization tandem 
mass spectrometry. Three peptides are encoded by uORFs that overlap the 
downstream main ORFs and the other peptide is encoded by a uORF that 
terminates prior to the main ORF [73]. To date, the mechanism by which uORF-
encoded peptides trans-regulate translation of the downstream main ORFs is still 
unclear.  
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Research Objectives 
MRP2/Mrp2 plays an important role in bile formation, detoxification, and drug 
disposition (absorption and elimination). Dysfunctional MRP2 expression results 
in Dubin-Johnson syndrome in human beings and changes in MRP2/Mrp2 
expression are also involved in all types of cholestasis. Changes in MRP2/Mrp2 
protein expression occur at the translation level under some conditions 
(pregnancy, PCN treatment, etc.) as well as the transcription level. To date, there 
have been no studies to investigate the mechanisms of translational regulation of 
MRP2/Mrp2. The work presented here characterized the uORFs of the human 
MRP2 and rat Mrp2 mRNAs as translational regulators in in vitro systems. 
Therefore, the uORF-mediated translational regulation provides a possible 
mechanic model that future studies could use to investigate the translational 
regulation of MRP2/Mrp2 protein expression under certain conditions, such as 
pregnancy, cholestasis, or PCN treatment.  
In Chapter Two, the studies were focused to investigate the hypothesis that 
the 5’UTRs of rat Mrp2, particularly the upstream ATGs, modulate translation. 
We compared the effect of multiple 5’UTRs of the rat Mrp2 mRNA on translation 
of the luciferase gene. Four ATGs are present in the longest 5’UTR (-213 
nucleotides relative to the Mrp2 ATG) of Mrp2. It is shown that the ATG at 
position -109 inhibited translation dramatically, compared with other ATGs.  
In Chapter Three, we continued to study the mechanism by which the uORF 
at position -109 of rat Mrp2 inhibited translation. In order to test whether the 
inhibitory effect exerted by this uORF was sequence-dependent, we compared 
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the translational efficiencies of the native and frame-shifted sequences in in vitro 
translation assays. We also tried to detect the presence of the peptide encoded 
by the uORF at position -109 in tissues (liver and kidney).  
In Chapter Four, we extended the research to investigation the hypothesis 
that the 5’UTRs of human MRP2 mediate translational regulation. The 5’UTRs of 
the human mRNA are more complicated; the longest 5’UTR contains seven 
upstream ATGs. Here, we investigated the effect of the 5’UTRs, particularly the 
upstream ATGs, on translation in transiently transfected HepG2 cells and in vitro 
translation. Finally, we examined the sequence-dependence of translational 
effects exerted by the uORF at position -105 (relative to the ATG of MRP2).  
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FIGURE AND LEGEND 
 
Figure 1.1. Schematic representation of eukaryotic translation initiation. 
The three factors of an mRNA controlling translation initiation are marked in the 
picture with the diamond shape, 1) m7G capped 5’ end, 2) stable stem-loop 
secondary structures, and 3) upstream translation initiation sites ATGs. 
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CHAPTER TWO 
TRANSLATIONAL REGULATION OF RAT MULTIDRUG RESISTANCE 
PROTEIN 2 (MRP2) IS MEDIATED BY UPSTREAM OPEN READING FRAMES 
(UORFS) IN THE 5’ UNTRANSLATED REGION (UTR) 
BACKGROUND 
Multidrug resistance protein 2 (rat Mrp2 or human MRP2), a member of the 
ATP-binding cassette gene superfamily of transport proteins, is present in the 
apical membrane of hepatocytes, enterocytes and renal proximal tubules. Mrp2 
protein mediates efflux of organic anions such as glutathione, glucuronide and 
sulfate conjugates against a concentration gradient from hepatocytes into bile 
[16, 19, 74, 75], and also contributes to bile flow by mediating canalicular 
excretion of glutathione (GSH) [76]. 
Regulation of Mrp2 expression has been characterized primarily at the 
transcriptional level in rats and mice. Exposure to activators of nuclear receptors, 
such as Nrf2, CAR and PXR, increases Mrp2 protein expression in rat primary 
hepatocyte cultures [23], while studies in mice have shown that CAR and Nrf2 
agonists, but not PXR agonists, increase Mrp2 mRNA expression [77, 78], 
supporting the importance of transcriptional regulation. However, in the rats 
treated with pregnenolone-16α-carbonitrile (PCN), a PXR agonist, hepatic Mrp2 
mRNA expression is unchanged, whereas Mrp2 protein expression is increased 
2-3 fold [46, 79, 80]. Ethinylestradiol treatment markedly decreases Mrp2 protein 
in the rat liver, while Mrp2 mRNA remains unchanged [26]. Similarly, hepatic 
Mrp2 protein in the pregnant rat is significantly decreased by 50%, while Mrp2 
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mRNA is unchanged [44, 45]. Along the rat small intestine, Mrp2 protein is 
decreased by 90% in the distal ileum relative to that in the jejunum, whereas 
Mrp2 mRNA does not change significantly [48]. The inconsistency between the 
changes in Mrp2 mRNA and protein expression indicates that under some 
conditions, rat Mrp2 protein expression undergoes post-transcriptional regulation.  
Post-transcriptional regulation of protein expression can occur through 
changes in mRNA stability, in the rate of protein degradation, or in the rate of 
protein synthesis. The minimal changes in Mrp2 mRNA expression in female 
control, pregnant and PCN-treated rats argue against significant differences in 
Mrp2 mRNA stability as likely to contribute to the mechanism of translation of rat 
Mrp2 that could account for the 4-5-fold differences in Mrp2 protein expression 
among these groups. We recently showed that altered rates of hepatic Mrp2 
protein degradation cannot explain the differences in its protein expression in 
control, pregnant and PCN-treated rats, whereas decreased and increased rates 
of Mrp2 protein synthesis were observed in pregnant and PCN-treated rats, 
respectively [46]. In the present studies, we therefore focused on the potential 
mechanism of translational regulation of Mrp2 protein synthesis.  
Accumulating evidence indicates that upstream open reading frames 
(uORFs) are important regulators of mRNA translation [64, 81, 82], which can be 
explained by the ribosomal scanning model. Translation of a downstream main 
open reading frame (ORF) of a gene by ribosomes occurs through leaky 
scanning of any ATGs in the 5’ untranslated region (5’UTR) when the sequence 
around the upstream ATGs is suboptimal [53], or through reinitiation when the 
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translation machinery is not dissociated from the mRNA chain after termination of 
translation of uORFs [64]. We identified four transcription initiation sites in rat 
hepatic Mrp2 cDNA that occur at -213, -163, -132, and -98, where the ATG of the 
Mrp2 coding gene is numbered +1, +2, and +3 [46] (Figure 2.1.A.). In the present 
study, we fused these Mrp2 5’UTRs upstream of the luciferase reporter gene and 
investigated their effect on luciferase expression in HepG2 cells in transient 
expression assays and on the translation efficiency of the luciferase transcript in 
in vitro translation assays. We also used ribonuclease protection assay (RPA) to 
identify transcription initiation sites in the rat liver, kidney and small intestine, and 
during postnatal development. We found that these tissues utilize different Mrp2 
transcription initiation sites, and that translation from these transcripts is greatly 
influenced by the presence of the uORF at -109 nucleotides.  
 
 
 
 
 
 
 
 
 
 
 
20 
MATERIALS AND METHODS 
Materials 
α-32P-UTP (800 Ci/mmol) and 35S-methionine (1000 Ci/mmol) were obtained 
from Perkin Elmer Life and Analytical Sciences (Boston, MA). Unless otherwise 
noted, all other chemicals were of analytical grade and of cell culture grade from 
Sigma Chemical Co. (St. Louis, MO), InvitrogenTM life technologies (Carlsbad, 
CA), Roche Diagnostics (Indianapolis, IN) and Fisher Scientific (Pittsburgh, PA). 
Restriction enzymes were obtained from Invitrogen and Promega (Madison, WI).  
 
Animals 
Adult female Sprague Dawley rats whose weights were 215±25 g were 
obtained from Harlan Industries (Indianapolis, IN). The rats had free access to 
water and food and were maintained on an automatically timed 12-h light/12-h 
dark cycle. All experimental protocols involving animals were approved by the 
Institutional Animal Care and Use Committee of the University of Kentucky, and 
conducted following National Institutes of Health guidelines for the care and use 
of laboratory animals. In order to determine postnatal changes, female pups were 
separated from moms at indicated times after birth, and tissues were immediately 
removed and frozen in liquid nitrogen until isolation of RNA.  
 
Ribonuclease protection assay (RPA)  
The neonatal and control (adult) rat liver, kidney, placenta, lung, and small 
intestine were removed immediately after decapitation and frozen in liquid 
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nitrogen. Total RNA was isolated using TRIzolTM reagent (Invitrogen) following 
the manufacturer’s instructions.  
The luciferase control vector (Promega) was fused at cloning sites Hind III 
and BamH I with the Mrp2 5’UTR cDNA sequence starting at -1 to -214 relative 
to the ATG (numbered as +1, +2, and +3) of the Mrp2 coding region. A double-
stranded 280 bp fragment containing the T7 promoter and the Mrp2 5’UTR was 
purified after the fusion luciferase vector was digested with Pvu II and BamH I. 
The α-32P-UTP labeled Mrp2 probe was prepared according to the instructions of 
the MAXIscript T7 kit (Ambion, Austin, TX), using the 280 bp fragment as 
template. RPA was performed following the procedure of the RPA III kit 
(Ambion). Briefly, total RNA was incubated with the Mrp2 probe in the mixture 
containing 0.5 M ammonium acetate and 2.5 volumes of ethanol. Following co-
precipitation of the probe with total RNA after incubation at -80°C for 90 min, the 
RNA pellet was washed once with 75% ethanol and dissolved in hybridization 
solution. The hybridization reaction was incubated at a decreasing temperature 
from 56°C to 36°C at the rate of 2°C per 2 hr. The single-stranded RNA was 
digested by RNAse A/T1 mix at 37°C for 1 hr. The fragments protected from 
RNAse digestion were identified by electrophoresis on 6% urea-PAGE gel. 
 
Plasmid construction 
The Mrp2 5’UTR cDNA is shown in Figure 2.1.A. The cDNA sequences of 
the Mrp2 5’UTRs (Figure 2.1.B.), L, M1, M2, and S1, were PCR amplified using 
the forward primers TRF1, TRF2, TRF3, and TRF4, respectively (Table 2.1). The 
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reverse primer for L and M1 PCR amplification was CONR (Table 2.1). The 
reverse primer for amplifying both M2 and S1 was T7R1 (Table 2.1). The 
fragments were ligated upstream of the ATG of the firefly luciferase reporter gene 
into the pGL3 control vector (Promega) for transient co-transfection assays in 
HepG2 cells, and into the T7 control vector (Promega) for in vitro translation 
assays.  
The cDNA sequences of the 5’UTRs, deL, deM, and S2, were PCR amplified 
using forward primers TRF1, TRF2, and TRF5, respectively, and the reverse 
primer TRRR that deleted 1 nucleotide from T7R1 (Table 2.1). These fragments 
were fused in the T7 control luciferase vector. As a result, ATG1 (at position -
109) is in-frame with the luciferase reporter gene ORF.  
uORFs were disrupted by introducing a point mutation into start codons, 
ATG→AAG, using the corresponding wildtype constructs as templates. The point 
mutations of the nucleotides T at -148 and -108 to A were termed “a” and “b”, 
respectively; and the mutation of the Kozak motif flanking the ATG at -109 
termed “c” (Figure 2.1.B.). All mutagenesis was performed according to the 
manufacturer’s instructions of the Quick-Change Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). All plasmids were confirmed by sequencing. 
 
HepG2 cell transient co-transfection assays  
HepG2 cells were cultured in DMEM/F12 (1:1) medium supplemented with 
10% charcoal-stripped fetal bovine serum (Hyclone Laboratories, Logan, UT), 
3.58 mM glutamine, 55 µg/ml gentamycin, and 1 µg/ml insulin (Invitrogen). One 
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day before transfection, culture medium was replaced by phenol red-free DMEM 
supplemented with 10% charcoal stripped FBS, glutamine, and gentamycin. The 
plasmids (1 µg) were transfected by the ProFectin mammalian transfection 
system-calcium phosphate (Promega) into HepG2 cells, together with 30 ng of 
pSV40-Ren (Promega) as an internal control for transfection efficiency. After 5-6 
h incubation, the transfection medium was replaced with maintenance medium. 
Cells were harvested 24 h later for measurement of the firefly and Renilla 
reniformis luciferase activities by the Dual-luciferase reporter assay system 
(Promega). The firefly luciferase activity was normalized to Renilla reniformis 
luciferase activity. 
 
In vitro translation assays 
The tested Mrp2 5’-UTR-luciferase constructs were linearized by Pvu II and 
Sac I. The capped and α-32P-UTP-labeled firefly luciferase transcripts that were 
fused with Mrp2 5’UTRs, were synthesized in vitro with the Pvu II-Sac I 
fragments as templates, according to the manufacturer’s instructions of 
mMESSAGE mMACHINE T7 kit (Ambion). Transcription efficiency was 
quantified by scintillation counting of α-32P-UTP incorporation into RNA. The 
integrity and size of the luciferase transcripts were verified by formaldehyde-
agarose gel electrophoresis. The luciferase protein was synthesized from the 
capped luciferase transcripts in vitro, according to the manufacturer’s procedure 
of the Rabbit Reticulocyte Lysate System (Promega). Briefly, 0, 2, 4, 10, or 20 ng 
of the luciferase transcript was added to a reaction mixture. The translation 
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reaction was immediately incubated at 30 °C for 60 min and terminated by 
moving onto ice. The firefly luciferase activity was measured by the Luciferase 
Assay System (Promega) according to the manufacturer’s instructions.  
 
In vitro expression in the Transcription/Translation coupled system 
The TnT quick Transcription/Translation coupled system (Promega) was 
used to translate the luciferase protein using tested constructs as templates. 
According to the manufacturer’s instructions, a reaction mixture (50 µl) containing 
40 µl of TnT Master Mix and 2 µl of 35S-methionine were incubated at 30 °C for 
90 min. The translated products were separated on 4-20% gradient denaturing 
SDS-PAGE and data processed using the STORM 840 Phosphoimager 
(Molecular Dynamics).  
 
Data analysis 
RPA bands were quantified by densitometry using Quantity One 1-D 
Analysis Software (Bio-Rad). Linear regression analysis was performed by 
GraphPad Prism 4.0.  
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RESULTS 
Identification of rat Mrp2 transcription initiation sites and the relative 
abundance in rat tissues by RPA 
Four transcription initiation sites have been identified at position -213, -163, -
132, and -98 in the 5’UTR of the rat hepatic Mrp2 mRNA cDNA (Figure 2.1.A.) 
[46]. We investigated the transcription initiation sites in the various rat tissues to 
determine if their use might be tissue-specific. The four transcription initiation 
sites were detected in the rat liver, with the site at position-98 as the primary site, 
and the one at position -132 as the secondary site (Figure 2.2.). The transcription 
initiation sites in other tissues were different from that in the liver. In the placenta 
and kidney, the primary site was located at position -132 and the secondary site 
was at position -98, while other sites were barely detected. The primary site in 
the lung was at position -98, while other transcription initiation sites not detected. 
In the jejunum, the primary and secondary sites were located at position -98 and 
-132, but located at position -132 and -98 in the ileum, respectively, while other 
sites not detected.  
We next investigated whether utilization of the transcription initiation sites 
might vary with age. In the liver, the ratio of expression of the transcript starting 
at position -132 to the one starting at position -98 was 0.73 ± 0.06 at Day 0, 
increased to 1.06 ± 0.10 at Day 10, and then decreased to 0.80 ± 0.03 in the 
adult (Figure 2.3.A.). In the kidney, the ratio was similar at Day 0 and Day 6 (≈ 4), 
and increased to 13.4 ± 1.2 in adulthood (Figure 2.3.B.). In the jejunum, the ratio 
was 1.2 ± 0.19 at Day 0, increased to 1.5 ± 0.02 at Day 20, and then decreased 
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to 0.87 ± 0.1 in the adult (Figure 2.3.C.). In the ileum, the ratio was very similar 
from Day 0 to adulthood (0.70 – 0.85) (Figure 2.3.D.). The data indicated that the 
changes in expression of Mrp2 transcripts with age were relatively minor 
compared to those among the tissues. 
 
Effect of the rat Mrp2 5’UTRs on expression of the luciferase reporter 
gene in the transiently transfected HepG2 cells 
In order to determine whether the various 5’UTRs differentially influenced 
Mrp2 protein expression, the effect of Mrp2 5’UTRs on expression of the firefly 
luciferase reporter gene was determined in the transiently transfected HepG2 
cells. Fusion plasmids were constructed by inserting Mrp2 5’UTRs into the pGL3 
control vector immediately upstream of the luciferase reporter gene. In addition, 
the wildtype 5’UTRs were altered by disruption of ATG1 at position -109 and 
ATG2 at position -149 to determine the influence of uORF1 and uORF2 on 
protein expression. Fusion plasmids were transiently cotransfected individually 
with pSV40-Ren into HepG2 cells, and the firefly luciferase activity normalized to 
the Renilla luciferase activity of cell extracts. 
When normalized to the ratio of Firefly/Renilla luciferase of the pGL3 control 
vector that is without any Mrp2 5’UTR (=1) (Figure 2.4.A., B.), the luciferase 
activities of L (the -213 nt transcript), Lb (L with a single mutation at ATG1 to 
AAG), and La+b (L with double mutations at ATG1 and ATG2 to AAG) were 0.39, 
0.8, and 0.93, respectively. Similarly, those of M1 (the -163 nt transcript), M1b 
(M1 with a single mutation at ATG1 to AAG), and M1a+b (M1 with double 
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mutations at ATG1 and ATG2 to AAG) were 0.23, 0.96, and 0.90, respectively. 
Therefore, L (the -213 nt transcript) decreased the luciferase activity about 60% 
relative to the control pGL3 vector (p<0.001), whereas disruption of ATG1 in L 
(Lb) increased the luciferase activity 2-fold relative to L (p<0.001). Disruption of 
the both ATG1 and ATG2 (La+b) slightly increased the luciferase activity in 
comparison to Lb (p>0.05). The wildtype M1 (the -163 nt transcript) expressed the 
lowest luciferase activity (25% of pGL3, p<0.001) (Figure 2.4.B.). Disruption of 
ATG1 in M1 (M1b) increased the luciferase activity 3-fold compared to M1 
(p<0.001), whereas disruption of both ATG1 and ATG2 (M1a+b) slightly 
decreased the luciferase activity compared to M1b (p<0.001). Taken together, 
these data implied that uORF1 was more important in regulation of expression 
compared to uORF2.  
 
Effect of the rat Mrp2 5’UTRs on translation efficiency of the luciferase 
transcript by in vitro translation assays 
Since the luciferase protein expression in HepG2 cells required both 
transcription and translation processes, we next investigated the influence of 
various rat Mrp2 5’UTRs on translation efficiency of mRNA. The capped 
luciferase transcripts were prepared using Pvu II-Sac I fragments as templates in 
which Mrp2 5’UTRs were located immediately upstream of the luciferase coding 
region. The capped luciferase transcripts were added to the rabbit reticulocyte 
lysate system to determine the effect of 5’UTRs on translation efficiency under 
conditions of linearity with respect to transcript concentration. Translation 
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efficiency was calculated from the linear relationship between the luciferase 
activities and mRNA concentrations.  
Translation efficiencies of the capped luciferase mRNAs with S1 (-98 nt), M2 
(-132 nt), and L (-213 nt) were 67-, 37-, and 15-fold higher than that of M1 (-163 
nt) (p<0.0001, Figure 2.5.A.). We investigated contribution of uORFs to the 
differences in translation efficiency of the various transcripts. Mutation of ATG1 to 
AAG in the -213 nt transcript (Lb) increased translation efficiency 3-fold, whereas 
mutation of ATG2 to AAG in the -213 nt transcript (La) decreased translation 
efficiency 80%, compared to the wildtype L (p<0.0001, Figure 2.5.B.). Compared 
to that of M1 (-213 nt), the translation efficiency of M1b containing mutation of 
ATG1 to AAG increased 31-fold (p<0.0001), while the translation efficiency of 
M1a containing mutation of ATG2 to AAG increased 6-fold (p=0.0026) (Figure 
2.5.C.). Compared to the -132 nt transcript (M2), a single mutation at ATG1 to 
AAG in M2 (M2b) increased translation efficiency 4-fold (p<0.0001), while 
disruption of the Kozak motif of uORF1 in M2 (M2c) increased translation 
efficiency only 1.7-fold (p=0.001, Figure 2.5.D.). 
 
In vitro expression in the Transcription/Translation coupled system 
The effect of uORF1 on translation efficiency suggested that ATG1 serves 
as a translation start site. To determine if translation could be initiated at uORF1, 
we inserted Mrp2 5’UTRs into the T7 control vector in such a way that ATG1 was 
in-frame with the luciferase ORF. When the plasmids containing deL and deM1 
were used as templates, a peptide of a higher molecular weight was observed in 
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the Transcription/Translation coupled system (Lanes 1 and 5 in Figure 2.6.). The 
higher molecular weight peptide was not observed when the plasmid containing 
S2 was used as template (Lane 3), or when uORF1 in deL and deM1 was 
disrupted (Lanes 2 and 4, Figure 2.6.). Detection of a higher molecular weight 
peptide of the plasmids containing uORF1 indicated that ATG1 can be used as 
an efficient translation initiation site.   
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CONCLUSIONS 
For the first time, we demonstrate by RPA that the transcription initiation 
sites at position -213, -163, -132, and -98 (Figure 2.1.A.) were differentially used 
in the rat liver, kidney, small intestine, lung and placenta (Figure 2.2.) and that 
their use varied little with age in the liver, kidney, and jejunum and ileum (Figure 
2.3.). In the jejunum, the primary and secondary transcription initiation sites were 
at position -98 and -132, respectively, whereas in the ileum, the primary and 
secondary sites were at position -132 and -98, respectively. In the kidney, the 
site at position -132 predominated, with other sites under detectable limits. In the 
liver, the site at position -98 was the primary site. 
This study also showed for the first time that Mrp2 5’UTRs were involved in 
translational regulation. uORF1 at position -109 had an inhibitory effect on 
translation. Disruption of uORF1 abolished the inhibitory effect of wild type 
5’UTRs (-213, -163, and -132 nt) on translation of the luciferase reporter gene in 
HepG2 cell transient transfection assays (Figure 2.4.) and in vitro translation 
assays (Figure 2.5.). The evidence that luciferase protein with a higher molecular 
weight was observed when uORF1 was fused in-frame with the luciferase ORF 
(Figure 2.6.) suggested that translation was efficiently initiated at uORF1. 
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FIGURES AND LEGENDS 
 
 
Figure 2.1. Construction of fusion plasmids. A. The full cDNA sequence of 
5’UTR of the rat Mrp2 gene. The ATGs are in bold and the gray-shaded 
sequences represent their uORFs. The ATG of the rat Mrp2 gene is numbered 
as +1, +2, and +3 and its ORF is termed ORF0. The upstream ATGs are located 
at position -109, -149, -197, and -213 and termed ATG1, ATG2, ATG3, and 
ATG4, respectively. Accordingly, the uORFs are termed uORF1, uORF2, 
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uORF3, and uORF4. uORF1 from position -109 to +62 contains 57 codons; 
uORF2 from position -149 to -123, 9 codons; uORF3 from position -197 to -189, 
3 codons; and uORF4 from position -213 to -166, 16 codons. uORF4 is in-frame 
with ORF0 and uORF1-3 are out-of-frame with ORF0. Transcription initiation 
sites at position -213, -163, -132, and -98 are marked with asterisks. B. 
Schematic representation of the fusion Mrp2 5’UTR-luciferase constructs. 
The inserts shown were fused in the pGL3 control vector or in the T7 luciferase 
control vector between the T7 promoter and the luciferase ORF. Mrp2 5’UTRs 
are shown as the lines to scale. The point mutations in the 5’UTRs are listed in 
the table. The italicized nucleotides were mutated to disrupt uORF1 and uORF2 
or Kozak motif of uORF1: “a”, mutation of the nucleotide T at position -148 to A; 
“b”, mutation of the nucleotide T at position -108 to A; “c”, mutation of both the 
nucleotides A at position -112 and G at -106 to T.  
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Figure 2.2. Identification of transcription initiation sites of the Mrp2 gene 
and the relative abundance in rat tissues by RPA. The α-32P-UTP-labeled 
Mrp2 probe of 280 nucleotides contains the Mrp2 5’UTR from position -1 to -214. 
Total RNA was incubated with the probe. Following hybridization, the single 
strand RNA was degraded by RNAse A/T1 Mix. The fragments protected from 
RNAse digestion were identified by electrophoresis on 6% urea-PAGE gel. Mrp2 
probe (lane 1) is the product of 20 µg of yeast without RNAse treatment.  
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Figure 2.3. The relative abundance of transcription initiation sites of the 
Mrp2 gene in neonatal rat tissues and adults by RPA. Rat pups were 
decapitated at day 0, 6, 10, 20, and adulthood. The liver, kidney, jejunum, and 
ileum were taken, frozen in liquid nitrogen, and stored at -80°C until isolation of 
total RNA. Liver RNA (10 µg) and 20 µg of kidney, jejunum, and ileum RNA were 
used. Mrp2 probe (lane 1) is the product of 10 µg of yeast RNA without RNAse 
treatment. The figure shown is a representative of three experiments. The 
histograms represent the ratio of the transcript starting at position -132 to the one 
at position -98 obtained, and represented as mean ± SD of three independent 
experiments.  
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Figure 2.4. Effect of Mrp2 5’UTRs on expression of the luciferase reporter 
gene in HepG2 cell transient cotransfection assays. Mrp2 5’UTR-luciferase 
constructs were cotransfected with pSV40-Ren into HepG2 cells. After 24 hours, 
the firefly and Renilla reniformis luciferase activities were measured. The effect of 
various 5’UTRs (A. L, -213 nt; B. M1, -163 nt) on luciferase expression is 
represented as the ratio of the firefly luciferase activity to Renilla reniformis 
luciferase activity. The assays were performed in triplicate. The data are 
normalized to the Luc/Ren ratio of the pGL3 control vector and represented as 
mean ± SEM. This work was done by Dr. Wei Li in the laboratory. The data were 
performed One-Way ANOVA and followed with Bonferroni’s pairwise 
comparison.  
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Figure 2.5. Effect of Mrp2 5’UTRs on translation efficiency of the luciferase 
reporter transcript by in vitro translation assays. Mrp2 5’-UTR-luciferase 
constructs were linearized by restriction enzymes Pvu II and Sac I. The 
fragments of Pvu II-Sac I were used as templates to synthesize the capped, 
Mrp2 5’UTRs-fused luciferase transcripts. The luciferase transcripts (0, 2, 4, 10, 
or 20 ng) were added to a rabbit reticulocyte lysate mixture. The translation 
reaction was incubated at 30°C for 60 min and terminated on ice. The lines 
represent the relationship of luciferase activities with respect to transcript 
concentrations. The statistical significance of the difference in the slopes was 
tested by GraphPad Prism 4.0. A. Translation of the 5’UTRs; B. L and its 
mutants; C. M1 and its mutants; D. M2 and its mutants.  
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Figure 2.6. In vitro expression in the Transcription/Translation coupled 
system. The rat Mrp2 5’UTR cDNA sequences were inserted into control T7 
luciferase vector to make ATG1 in-frame with the luciferase ORF. The 5’UTRs of 
deL and deM1 contain ATG1 while S2 does not. The point mutation of 
ATG1→AAG disrupted uORF1 in deL and deM1, obtaining deLb and deM1b 
constructs. These constructs were used in the Transcription/Translation coupled 
system. The translated products were separated on 4-20% gradient SDS-PAGE. 
Data were processed using STORM 840 Phosphoimager. This work was done by 
Dr. Wei Li in the laboratory.   
39 
Table 2.1 Primers used for PCR amplification of the rat Mrp2 5’UTR cDNAs 
Name Sequence (5’-3’) cloning site 
TRF1 
TRF2 
TRF3 
TRF4 
TRF5 
CONR 
T7R1 
T7R2 
TRRR 
5’ ggaagcttatgtctgctcactggga 3’ 
5’ ggaagcttattaagtcgtcaggatga 3’ 
5’ tcaaagcttaggcctttaactgggctg 3’ 
5’ ggaaagcttacggtgcactttaacatctg 3’ 
5’ ggaagcttagaggaaaaagtaaaggag 3’ 
5’ accccatggtaatgctctcctcgcgc 3’ 
5’ ggggatccgaatgctctcctcgcgc 3’ 
5’ tttggatccaatgctctcctcgcg 3’ 
5’ ggggatccaatgctctcctcgcgc 3’ 
Hind III 
Hind III 
Hind III 
Hind III 
Hind III 
Nco I 
BamH I 
BamH I 
BamH I 
 
The cloning sites are underlined.  
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CHAPTER THREE 
DETERMINATION OF THE SEQUENCE DEPENDENCE  
OF TRANSLATIONAL INHIBITORY EFFECT EXERTED BY UORF1  
AND INVESTIGATION REGARDING EXPRESSION OF ITS ENCODED 
PEPTIDE (PEP56) IN RAT TISSUES 
BACKGROUND 
Several studies show that nascent peptides encoded by uORFs mediate 
regulation of translation [64]. This mechanism depends on the amino acid 
sequence of the encoded peptide. At present, at least six eukaryotic mRNAs 
have been found in which translation is repressed by their uORFs in a sequence-
dependent way [64].  
S-Adenosylmethionine decarboxylase (AdoMetDC) is a key regulated 
enzyme in the biosynthesis of the polyamines spermidine and spermine. The 
mRNA of AdoMetDC contains a single short uORF encoding a peptide: MAGDIS 
[64]. Missense but not synonymous mutation of each codons shows that 
repression of translation exerted by this uORF encoding MAGDIS stringently 
requires the codons at positions 4 and 5. No amino acid substitution of the 
naturally occurring aspartic acid at codon 4 yields a full suppression of 
translation. Only valine could substitute productively for isoleucine at codon 5 
[68, 69].  
Retinoic acid receptor-β2 (RARβ2) mRNA has a complex 5’UTR. Among the 
five uORFs, uORF4 of RARβ2 mRNA encodes a translational inhibitory peptide. 
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Missense mutations show that the amino acids at position 5, 6, 12, and 13 of this 
peptide are critical for translational inhibition of uORF4 [83].  
The human cytomegalovirus (CMV) virion glycoprotein gpUL4 mRNA 
contains three uORFs. Using deletion, frameshifting, and missense substitution 
of the amino acids of the encoded peptide of uORF2, Degnin et al [84, 85] found 
that uORF2 exerts translational inhibition in an amino acid sequence dependent 
way. They also reported that this peptide acts in a cis-dependent manner.  
Although conserved sequences are not found in these peptides encoded by 
uORFs or in the nucleotide sequences of uORFs, it is believed that a uORF-
encoded peptide can cause ribosome stalling by association with RNA or 
proteins of the scanning ribosomes so as to inhibit their function [64].  
We have demonstrated by point mutation in Chapter Two that uORF1 at 
position -109 (shown in Figure 2.1A) of the rat Mrp2 mRNA down-regulates 
translation of the downstream main ORF and the scanning ribosomes efficiently 
recognize ATG1 at position -109 and initiate translation of uORF1. Therefore, we 
next investigated the role of the nascent peptide encoded by uORF1 in 
controlling translation of the downstream main ORF.  
Since uORF1 in the rat Mrp2 mRNA encodes a 56 amino acid peptide. It is 
unrealistic to mutate, at least initially, each single codon to determine the amino 
acid sequence dependence. Therefore, logically, we first divided the peptide into 
three segments: first segment (rF), middle segment (rM), and last segment (rL) 
(shown in Figure 3.1.), each of which encodes 22 amino acids. After the middle 
and last segments were found to have stronger inhibitory effect on translation in 
42 
in vitro translation assays, we further confirmed this by studying the frame-shifted 
mutants of the middle and last segments. To narrow down the amino acid range 
that would be critical to the inhibitory effect of uORF2, the combined amino acid 
segments of the middle and last segments were further divided into three pieces 
each of which contained 11 codons: r11aa_1, r11aa_2, and r11aa_3 (shown in 
Figure 3.1.). Finally, the translational efficiencies of the nature and frame-shifted 
sequences of uORF1 (r56 and ∆r56, shown in Figure 3.1.) were examined in in 
vitro translation assays. We also investigated whether uORF1 at position -109 is 
a cis- or trans-acting regulator of translation in vitro. In addition, we also 
expressed the peptide encoded by uORF2 of the rat Mrp2 mRNA in the TnT 
system, and also tried to detect this peptide in the rat liver and kidney. 
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MATERIALS AND METHODS 
Materials 
L-35S-Methionine was purchased from Amersham (UK), and protein A/G 
Plus-agarose was from Santa Cruz. PAS is a rabbit polyclonal antibody to a 17 
amino-acid epitope (SAFPEEKUKEKQYNHRR) of the peptide of 56 amino acids 
encoded by uORF1 (Pro-Sciences) (named Pep56). The construct 
pET21_Pep56 was prepared by EnzyMax by cloning the sequence of uORF1 
into the expression vector pET21. Expression of Pep56 tagged with 6xHis at the 
N-terminal (molecular weight: 7.2 kDa) was induced by IPTG in E. Coli. Pep56-
His was used as the positive control of Pep56 in the following work.  
 
Plasmid construction 
A schematic representation of the fusion luciferase constructs used is shown 
in Figure 3.1. All inserts were fused between the T7 promoter and the luciferase 
ORF at the Hind III restriction site. Using the pair of primers of pepF/pepR (all 
primers are shown in Table 3.1.), the sequence from position -109 to +92 was 
PCR-amplified from the genomic cDNA library prepared from the rat liver, and 
cloned into the luciferase T7 control vector, obtaining the plasmid rMrp2_56. The 
nucleotides GTGAGA were inserted into rMrp2_56 before ATG1 with the primers 
KoF/KoR to maintain the Kozak motif intact, thus obtaining the plasmid r56. The 
plasmid ∆r56 was prepared by frame-shifting uORF1 according to the following 
sequence: 1) A potential stop codon formed after frame-shifting was deleted by 
mutation of T at position -38 to C with the primers MutF/MutR; 2) A frame-shifting 
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mutation was performed by deletion of the nucleotides GA after ATG1 following 
insertion of the nucleotides AA before TGA of uORF1 with the pairs of primers 
DelF/DelR and InsF/InsR, respectively.  
The plasmid rF was obtained by deletion of the sequence from position -43 
to +61 with the plasmid rMrp2_56 as template and then by insertion of the 
nucleotides GTGAGA before ATG1, using two pairs of primers of rFna/rRna and 
KoF/KoR, respectively. Thus, the insert rF contained the first 22 codons of 
uORF1. 
The plasmid rM was prepared by sequential deletion of the sequences from 
position -104 to -42 and from position +16 to +61 nt from the plasmid r56, using 
two pairs of primers, M1F/M1R and M2F/ M2R, respectively. Thus the insert rM 
contains the middle 22 codons of uORF1. Frame-shifting prepared the plasmid 
∆rM through sequential deletion of two adenosines after ATGGAG and insertion 
of two adenosines before TGA, using two pairs of primers of delMF/delMR and 
insMF/insMR, respectively. The plasmid rL was prepared by deleting the 
sequence from position -104 to -2 from the plasmid r56 with the pair of primers of 
LF/LR. The insert rL contains the last 22 codons of uORF1, but overlaps the 
sequence of rM. The plasmid ∆rL was prepared by deletion of an adenosine after 
ATGGAG and insertion of an adenosine before TGA, using two pairs of primers 
of delLF/delLR and insLF/insLR, respectively. 
With a pair of primers M3F/M3R, the sequence from position -10 to +61 was 
deleted from the plasmid rM to obtain r11aa_1. The plasmid r11aa_2 was 
prepared by deletion of the sequences from position -104 to -13 and +24 to +61 
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from the plasmid r56, using two pairs of primers of M4F/M4R and M5F/M5R, 
respectively. The plasmid r11aa_3 was constructed by deletion of the sequences 
from position -104 to +23 from the plasmid r56, using the pair of primers of 
M6F/M6R. Each of the obtained inserts of r11_1, _2, and _3 contains 11 codons.  
The plasmid r56_LucAAG was obtained by mutation of the ATG of the 
luciferase gene to AAG to disrupt the luciferase ORF, using the plasmid r56 as 
template and the pair of primers MutLucF/MutLucR.  
In all of these constructed plasmids, the sequences upstream of the start 
codon and downstream of the stop codon were maintained as in the native Mrp2 
gene. All primers used are listed in Table 3.1. Mutagenesis was performed 
according to the manufacturer’s instructions of Quick-Change Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). All plasmids were confirmed by 
forward sequence sequencing reactions. 
 
In vitro translation assays 
The template of about 1.8 kbp was obtained by linearizing each tested fusion 
luciferase construct with restriction enzymes Pvu II and Sac I. The capped-end 
luciferase transcripts were prepared and randomly labeled by α-32P-UTP by in 
vitro transcription reactions. To quantify the RNA yield, incorporation efficiency of 
α-32P-UTP into RNA was determined by scintillation counting. Free nucleotides in 
the reaction mixture were removed using NucAway™ Spin Columns (Ambion). 
The luciferase transcripts (0, 2, 4, 10, 20, and 40 ng) were added to the reaction 
mixtures and incubated at 30 °C for 60 min and terminated on ice. The firefly 
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luciferase activity was measured by the Luciferase Assay System (Promega) 
according to the manufacturer’s instructions. The best linear fit of the relationship 
between luciferase activities and mRNA concentrations was determined using 
GraphPad Prism 4.0. The slopes of these lines represent translation efficiencies. 
 
Expression of Pep56 in the Transcription/Translation coupled system 
(TnT system).  
pcDNA3.1-r56aa was obtained by cloning the fragment from position -122 to 
+67 into the pcDNA3.1 vector (Invitrogen) at the Hind III and Xho I restriction 
sites. The TnT quick Transcription/Translation coupled system (Promega) was 
used to translate Pep56. According to the manufacturer’s instructions, a reaction 
mixture (50 µl) containing 40 µl of TnT Master Mix, 2 µl of 35S-methionine, 1 µg of 
pcDNA3.1 or pcDNA3.1_r56aa was incubated at 30 °C for 60 min. The reaction 
(1 or 2 µl) products were loaded and separated on 16% Tricine gel (Invitrogen). 
The gel was dried for 1 h at 80ºC and then developed at -80ºC for two weeks.  
 
Western Blot 
Female Sprague Dawley rats (weight=200-250 g) were sacrificed to obtain 
kidney and liver tissues. Tissues were homogenized in lysis buffer with a Dounce 
homogenizer. Cytosolic fraction was obtained by sequential centrifugation of 
homogenate at 9,000 g at 4°C for 20 min and 100, 000 g at 4°C for 60 min. 
Protein concentrations were determined by means of the Bio-Rad protein assay. 
Samples were boiled in 2x Tricine SDS sample buffer (Invitrogen) at 90°C for 3 
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min before being loaded on a 16% Tricine gel. Proteins were transferred to 
Protran® nitrocellulose filters by electrophoresis in transfer buffer for 2 hrs. Filters 
were incubated with PAS (1:200 in 1xT TBS with 5% milk) at 4°C overnight. After 
washing twice with 1x T-TBS at room temperature for 15 min, the secondary 
antibody (peroxidase-conjugated anti-rabbit IgG, 1:5000 in 1xT-TBS buffer with 
5% milk) was incubated with filters at room temperature for 1 hr. Then filters were 
washed twice again and developed using the Amersham enhanced 
chemiluminescence detection system. 
 
Titration with the antigen peptide  
The rat kidney homogenate (100 µg) and 0.1 µg of the positive control 
peptide (Pep56-His) were run on a 16% Tricine gel and transferred onto 
Protran® nitrocellulose filters. Before the Protran filter was incubated with the 
primary antibody, the antibody (PAS) was incubated with the 17-amino acid 
antigen peptide (0, 10, 100, 1000 ng) at 4°C for 3 hr, rotating on an end-to-end 
rotator. The Protran filter was then incubated with the secondary antibody 
(peroxidase-conjugated anti-rabbit IgG) and developed using the Amersham 
enhanced chemiluminescence detection (ECL) system.  
 
Immunoprecipitation  
Rat kidney homogenate (100 µg protein) was incubated with 120 µl RIPA 
buffer and 3 or 6 µg PAS at 4°C overnight on an end-to-end rotator. The next 
day, 40 or 60 µl of Protein A/G Plus-agarose was added into the mixtures with 3 
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or 6 µl PAS, respectively, and incubated at 4°C overnight on an end-to-end 
rotator. The pellets were collected by centrifugation at 2500 rpm at 4°C for 5 min 
and then gently washed 4 times with RIPA buffer. After the final wash, 
supernatants were carefully aspirated and discarded. The pellets were 
resuspended in 20 µl of 2x Tricine SDS sample buffer and boiled at 90°C for 3 
min. Then beads were spun down at 2500 rpm for 5 min and the supernatants 
were loaded in a 16% Tricine gel for Western blot analysis.  
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RESULTS 
Effect of the amino acid sequence of uORF1 on translation efficiency of the 
luciferase transcript in in vitro translation assays 
We have shown that ATG1 has an inhibitory effect on translation (Figure 
2.5.) and that it was able to be recognized efficiently by ribosomes since a longer 
luciferase protein was translated in the TnT system (Figure 2.6.). The next 
investigation was focused on determining whether this inhibitory translation is 
dependent on the amino acid sequence encoded by uORF1. We cloned uORF1, 
either intact or in 3 segments containing 22 or 11 amino acids into the control T7 
luciferase vector. We investigated whether the peptide and these segments 
might affect translation of the luciferase transcript. All segments shared the same 
ATG and its Kozak motif sequence, and the same stop codon and its 
downstream sequence as shown in Figure 3.1.  
When the sequence of uORF1 was divided into three segments (rF, rM, and 
rL), each of which encodes 22 amino acids, translation efficiencies of rM and rL 
were 1.6- and 2.6–fold lower than that of rF (p<0.0001), while the translation 
efficiency between rM and rL was similar (p=0.0014) (Figure 3.2.A.). When the 
amino acid sequence of rM was scrambled by frame-shifting, translation 
efficiency of ∆rM was 5.7-fold higher than that of the native rM (p<0.0001, Figure 
3.2.B.). Similarly, ∆rL increased translation efficiency 5.3-fold compared to rL 
(p<0.0001, Figure 3.2.C.). Thus, the amino acids of Pep56 without the first 22 
amino acids contributed more to the translational inhibitory effect. Therefore, the 
sequence of the last 34 codons was further divided into three pieces (shown in 
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Figure 3.1.). Each of the three sequential pieces encodes 11 or 12 amino acids. 
Translation efficiencies of r11aa_1, r11aa_2 and r11aa_3 were essentially the 
same (p=0.0019, Figure 3.2.D.). Finally, the translation efficiency of the luciferase 
transcript with the sequence of uORF1 (r56) was 1.29-fold higher than that with 
the frame-shifted sequence (∆r56) (p=0.00015, Figure 3.2.E.).  
 
Is the effect of uORF1 cis- or trans- acting? 
We have shown that uORF1 exerted a translational inhibitory effect when 
present upstream of the luciferase reporter transcript, and its encoded Pep56 
was expressed in the Transcription/Translation coupled system. In this 
experiment, we further investigated whether uORF1 is a cis- or trans- factor on 
translation.  
The luciferase ORF was disrupted in the plasmid r56_LucAAG. The 
luciferase transcript alone or both the luciferase transcript along with the 
r56_LucAAG transcript (0, 2, 4, 10, 20, and 40 ng of each) were added into the in 
vitro translation reaction mix. After incubation at 30ºC for 1 hr and termination on 
ice, the luciferase activities were measured. The translation efficiency of 
T7Luc_ctrl in the presence of r56_LucAAG was 97% of that in the absence of 
r56_LucAAG (p=0.91, Fig3.3.). Therefore, there was no difference shown in 
translational efficiency between the luciferase transcripts alone or together with 
the r56_LucAAG transcript. That is, uORF1 did not have a trans-acting effect on 
translation through its encoded peptide (Fig3.3.). 
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In vitro expression of Pep56 in the Transcription/Translation coupled 
system 
To determine if translation can efficiently initiate at ATG1, terminate at the 
stop codon at position +62, and express Pep56 (MW: 6.8 kDa), the plasmid 
pcDNA3.1-r56aa containing the segment from position -122 and +67 was 
incubated with the TnT reaction mixture and the newly synthesized peptide was 
labeled in the presence of L-35S-Methionine. A peptide was observed at 6.8 kDa 
in the lane of pcDNA3.1_r56aa, with no bands showing in the lane of the control 
plasmid pcDNA3.1 (Figure 3.4.). 
 
Detection of Pep56 expression in the rat kidney and liver 
We have shown that Pep56 was able to be expressed in vitro. We therefore 
questioned whether Pep56 is expressed in vivo. The theoretical molecular weight 
of Pep56 is 6.8 kDa. PAS was used as the primary antibody in Western blot 
analysis and Pep56-His was used as the positive control (Figure 3.5.). Although 
there was no band observed at 6.8 kDa, a peptide (about 14 kDa) was detected 
in the kidney homogenate at a higher level than in the liver homogenate, but was 
not found in the cytosolic fraction of either kidney or liver.   
Two more experiments were performed to determine whether the 14 kDa 
peptide might be an oligomer of Pep56. In the first experiment, titration of PAS 
with the antigen peptide (Figure 3.6.) showed that this band disappeared when 
10 ng of the antigen peptide was pre-incubated with PAS, in line with the fact that 
the positive control was titrated out gradually by antigen peptide (10, 100, and 
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1000 ng). Second, in the experiment of immunoprecipitation (Figure 3.7.), when 3 
µg of PAS and 40 µl of Protein A/G were used (lane 2-5), the band of 14 kDa did 
not appear in the pull-down products (lane 2 and 4) or their supernatants (lane 3 
and lane 5) of either kidney homogenate alone (lane 2 and 3) or in the presence 
of the positive control (lane 4 and 5), even though the positive control was 
successfully immunoprecipitated by PAS (lane 4). When 6 µg of PAS and 60 µl 
of Protein A/G were used (lane 6-9), the band appeared but was not able to be 
seen separately from non-specific bands in the immunoprecipitated products 
(lane 6 and 8), and it didn’t appear in the supernatants (lane 7 and 9) of either 
kidney homogenate alone (lane 6 and 7) or in the presence of the positive control 
(lane 8 and 9). More Pep56-His was immunoprecipitated in the mixture of the 
positive control plus kidney homogenate by 6 µg of PAS and 60 µl of Protein A/G 
(lane 8) than by 3 µg of PAS and 40 µl of Protein A/G (lane 4).  
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CONCLUSIONS 
To investigate whether the translational inhibition exerted by uORF1 at 
position -109 was dependent on its encoded amino acid sequence, uORF1 was 
divided into three segments (rF, rM, and rL) each of which encodes 22 amino 
acids. The data showed that rM and rL inhibited translation more efficiently than 
rF (Figure 3.2.A), suggesting that the amino acids in the segments of rM and rL 
were critical for translational inhibition exerted by uORF1 at position -109. This 
was further confirmed by the 5-6-fold higher translation efficiencies of the frame-
shifted sequences of ∆rM and of ∆L, compared to those of the native segments 
of rM and rL (Figure 3.2.B and C), respectively. However, when we narrowed 
down the amino acid range by further dividing the last 34-codon segment into 
three pieces (r11aa_1, r11aa_2, and r11aa_3), there was no difference observed 
in translation efficiency between r11aa_1, r11aa_2, and r11aa_3 (Figure 3.2.D). 
Also, when we finally examined the full-length 56 amino acid peptide, we 
observed no difference in the translation efficiencies between the native and 
altered amino acid sequences of uORF1 (r56 and ∆r56, respectively) (Figure 
3.2.E). Therefore, the last 34 amino acids in uORF1 work together in inhibiting 
translation.  
Further, the translational inhibition exerted by uORF1 was demonstrated  not 
to be trans-acting (Figure 3.3.B.), indicating that these amino acids may stall the 
scanning of ribosomes before the translation of uORF1 is finished, even though 
the peptide encoded by uORF1, Pep56 (MW=6.5 kDa), was expressed in the 
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TnT system (Figure 3.5.). However, we were unable to detect Pep56 in the rat 
liver or kidney. 
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FIGURES AND LEGENDS 
 
Figure 3.1. Schematic representation of construction of plasmids. All 
constructs shown were used to investigate the sequence dependence of uORF1 
on translation. Inserted sequences are shown as bold solid lines to scale and 
dashed lines represent the deleted sequences. All inserts shown were fused in 
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the T7 luciferase control vector between the T7 promoter and the luciferase 
coding region at the Hind III restriction site. Solid bars represent start codons and 
solid circle stop codons. The point mutations are shown as italic. The strike-
through nucleotides (like AA) present the deleted ones. Inserted nucleotides are 
indicated by solid triangles underneath the nucleotides. The unfilled arrows point 
to the ligation locations. r56 is the native sequence from position -115 to +92. 
∆r56 is the scrambled sequence obtained by frame-shifting r56. The insert of rF 
from position -115 to -44 encodes the first 22 amino acids of Pep56; rM from 
position -43 to +17, the middle 22 amino acids; rL from position -1 to +61 nt, the 
last 22 amino acids but shares amino acids with rM. ∆rM is a frame-shifted 
sequence of rM, and ∆rL a frame-shifted sequence of rL. The inserts of r11aa_1, 
r11aa _2, and r11aa _3 were obtained by dividing the sequence from position -43 
to +61 into three fragments each of which encodes 11 or 12 amino acids. All of 
these constructs share the same start codon and its upstream sequence, and the 
same stop codon and its downstream sequence. 
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Figure 3.2. Sequence dependence of uORF1 on translation by in vitro 
translation assays. The capped fusion luciferase transcripts (2, 4, 10, 20, and 
40 ng) were added to the reaction mixtures and incubated at 30ºC for 1 hr and 
then terminated on ice. The luciferase activity was measured. The straight lines 
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are the best fit of the relationship between luciferase activities and mRNA 
concentrations. The slopes represent translation efficiencies. This graph is a 
representative of two experiments. The statistical significance of the difference 
between the slopes was tested by GraphPad Prism 4.0.  
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Figure 3.3. Determination of the cis- or trans-acting effect of uORF1 on 
translation by in vitro translation assay. A. Schematic representation of the 
plasmid constructs. The sequence of position -115 to +92 of the rat Mrp2 5’UTR 
cDNA was inserted at Hind III restriction enzyme site in the T7 luciferase control 
vector (T7Luc_ctrl). The luciferase ORF in the plasmid r56_LucAAG was 
disrupted by mutation of the ATG of the luciferase gene to AAG. B. In vitro 
translation assays. The luciferase control transcript alone or together with the 
transcript of r56_LucAAG (2, 4, 10, 20, and 40 ng of each) were added to 
reaction mixtures and incubated at 30ºC for 1 hr and then terminated on ice. The 
luciferase activity was measured. The straight lines are the best fit of the 
relationship between luciferase activities and mRNA concentrations. The slopes 
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represent translation efficiencies. The statistical significance of the difference 
between the slopes was tested by GraphPad Prism 4.0.  
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Figure 3.4. Expression of Pep56 in the Transcription/Translation coupled 
system. A. The schematic representation of pcDNA3.1-r56aa constructs. The 
sequence from position -122 to +67 was cloned into the pcDNA3.1 vector at the 
Hind III and Xho I restriction sites. B. Expression of Pep56 in the TnT system. 
The control pcDNA3.1 vector (1 µg) or the pcDNA3.1-r56aa vector (1 µg) was 
added into the TnT reaction mixtures that contained L-35S-Methionine and 
incubated at 30ºC for 1 hr. The reaction products (1 or 2 µl) were run on a 16% 
Tricine gel. This is representative of two experiments.  
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Figure 3.5. Detection of Pep56 in the rat liver and kidney by Western Blot. 
The homogenates (100 µg of each) and the cytosol (78 µg of each) of liver and 
kidney were loaded on 16% Tricine gel for western blot analysis. Lane 1 is the 
positive control, Pep56-His (0.1 µg). Lane 2 and 3, the liver homogenate; Lane 4 
and 5, the kidney homogenate; Lane 6 and 7, the liver cytosol; and Lane 8 and 9, 
the kidney cytosol. The protein ladders are indicated by arrows.   
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Figure 3.6. Titration with the antigen peptide. The rat kidney homogenate 
(100 µg) and 0.1 µg of Pep56-His were run on 16% Tricine gel and transferred 
onto Protran® nitrocellulose filters. Before incubated with the filter, the primary 
antibody of PAS (1:200 in T-TBS) was incubated with the 17-amino acid antigen 
peptide (10, 100, 1000 ng) at 4°C for 3 hr. “K” represents the kidney homogenate 
and “+” represents Pep56-His. 
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Figure 3.7. Immunoprecipitation of the rat kidney homogenate with PAS. 
The rat kidney homogenate (1000 µg) was used in immunoprecipitation and pull-
down products was run on a 16% Tricine gel. “K” represents the kidney 
homogenate (1000 µg). Pep56-His (0.1 µg) was used in this experiment. S2, S4, 
S6, and S8 are supernatants of the lanes 2, 4, 6, and 8, respectively, after 
immunoprecipitation. Lanes 2-5 were all pulled down with 3 µg of PAS and 40 µl 
of Protein A/G plus agarose. Lanes 6-9 were pulled down with 6 µg of PAS and 
60 µl of Protein A/G plus agarose. The protein ladders were indicated by arrows.  
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Table 3.1. Primers used in site-directed mutagenesis for determination of 
sequence dependence 
Primers Sequence constructs 
pepF 5’atcaagcttatggagaaagcacg3’ 
pepR 5’atcaagcttagaacagtttgctca3’ 
rMrp2_56 
KoF 
5’ctatagggagacccaagcttgtgagaatggagaaagcacggt
gca3’ 
KoR 5’tgcaccgtgctttctccattctcacaagcttgggtctccctatag3’ 
r56 &rF 
MutF 5’ggagaaacagtacaatcacagaagagtcttcgtaacag3’ 
MutR 5’ctgttacgaagactcttctgtgattgtactgtttctcc3’ 
DelF 5’gacccaagcttatggaaagcacggtg3’ 
DelR 5’caccgtgctttccataagcttgggtc3’ 
InsF 5’gaaagtccagaggcaatgacctgcctctttg3’ 
InsR 5’caaagaggcaggtcattgcctctggactttc3’ 
∆r56 
rFna 
5’gctttcccagaggaaaaagtaaaggagaaacagtactgacct
gcctctttgttttgagcaaactgttctaag3’ 
rRna 
5’cttagaacagtttgctcaaaacaaagaggcaggtcagtactgttt
ctcctttactttttcctctgggaaagc3’ 
rF 
M1F 
5’cactatagggagacccaagcttgtgagaatggagaatcataga
agagtcttcgtaacagaagc3’ 
M1R 
5’gcttctgttacgaagactcttctatgattctccattctcacaagcttg
ggtctccctatagtg3’ 
rM 
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M2F 
5’cgaggagagcattatggacaagttctgcaatgacctgcctctttg
ttttgagcaaactgttc3’ 
M2-R 
5’gaacagtttgctcaaaacaaagaggcaggtcattgcagaactt
gtccataatgctctcctcg3’ 
LF 
5’cgactcactatagggagacccaagcttgtgagaatggagtatg
gacaagttctgcaactctactttttgggatctctc3’ 
LR 
5’gagagatcccaaaaagtagagttgcagaacttgtccatactcc
attctcacaagcttgggtctccctatagtgagtcg3’ 
rL 
delMF 5’cccaagctttgtagaatggagtcacagaagagtcttcgtaac3’ 
delMR 5’gttacgaagactcttctgtgactccattctacaaagcttggg3’ 
insMF 5’agagcattatggacaagttctgcaaaatgacctgcctcttt3’ 
insMR 5’aaagaggcaggtcattttgcagaacttgtccataatgctct3’ 
∆rM 
delLF 5’ccaagcttgtgagaatggagttggacaagttctgca3’ 
delLR 5’tgcagaacttgtccaactccattctcacaagcttgg3’ 
insLF 5’ggaaagtccagaggcatgacctgcctctttg3’ 
insLR 5’caaagaggcaggtcatgcctctggactttcc3’ 
∆rL 
M3F 
5’catagaagagtcttcgtaacagaagcgcgatgacctgcctcttt
gttttgagcaaactgttc3’ 
M3R 
5’gaacagtttgctcaaaacaaagaggcaggtcatcgcgcttctgt
tacgaagactcttctatg3’ 
11aa_1 
M4F 
5’ctatagggagacccaagcttgtgagaatggagggagagcatt
atggacaagttctgcaactc3’ 
11aa_2 
67 
M4R 
5’gagttgcagaacttgtccataatgctctccctccattctcacaagc
ttgggtctccctatag3’ 
M5F 
5’gagcattatggacaagttctgcaactctactgacctgcctctttgttt
tgagcaaactgttc3’ 
M5R 
5’gaacagtttgctcaaaacaaagaggcaggtcagtagagttgca
gaacttgtccataatgctc3’ 
M6F 
5’ctatagggagacccaagcttgtgagaatggagtttttgggatctct
cattactggaaagtcc3’ 
M6R 
5’ggactttccagtaatgagagatcccaaaaactccattctcacaa
gcttgggtctccctatag3’ 
11aa_3 
MutLucF 5’gcccggatccaaaaggaagacgccaaaaac3’ 
MutLucR 5’gtttttggcgtcttccttttggatccgggc3’ 
r56_LucAAG 
 
 
 
 
 
 
 
 
 
 
 
68 
CHAPTER FOUR 
TRANSLATIONAL REGULATION OF HUMAN MULTIDRUG RESISTANCE 
PROTEIN 2 (MRP2) IS MEDIATED BY THE 5’ UNTRANSLATED REGIONS 
BACKGROUND 
Studies in patients and human liver tissues have shown that expression of 
human hepatic MRP2 protein undergoes post-transcription regulation. A poor 
correlation between the human MRP2 mRNA levels and protein has been 
observed in patients with icteric inflammatory cholestasis [49] and in LPS treated 
human liver slices [51]. In the cancerous kidney cortex tissue of clear-cell renal 
cell cancer (CCRCC) and non-CCRCC patients, a significantly decreased MRP2 
protein was observed compared to that in the normal cortex tissues, but the 
mRNA level of MRP2 did not confirm this [86]. Expression of human MRP2 
protein is reduced by obstructive cholestasis in the intestine, while the level of 
mRNA is not affected [87]. There are no studies on the mechanisms of 
translational regulation of the human MRP2 gene to date  
The 5’ flanking region of the human MRP2 gene was first sequenced by 
Tanaka et. al [22], who identified three initiation sites of transcription (at position -
247, -204, and -99 relative to the ATG of human MRP2), based on the 5’ rapid 
amplification capped end assay (5’RACE) [22]. One of the similarities between 
Mrp2 and MRP2 mRNAs is the presence of multiple upstream translation start 
sites (ATGs) in the 5’UTRs, although the human MRP2 mRNA is more complex 
in terms of uORFs that rat. The cDNA sequence of the longest 5’UTR and the 
organization of uORFs of the human MRP2 gene are shown in Figure 4.1. There 
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are seven upstream ATGs in the cDNA sequence of the longest 5’UTR at 
position -74, -105, -137, -146, -173, -180, and -199 (relative to the ATG of human 
MRP2), which are termed ATG1, ATG2, ATG3, ATG4, ATG5, ATG6, and ATG7, 
respectively. Accordingly, the uORFs of these ATGs are termed as uORF1, 
uORF2, uORF3, uORF4, uORF5, uORF6, and uORF7. Only one upstream ATG 
in the human MRP2 5’UTR, ATG2 (at position -105), has a perfect Kozak motif 
(A at position -3 and G at +4 relative to ATG2). However, unlike uORF1 at 
position -109 in the rat Mrp2, the human uORF2 at position -105 is in-frame with, 
but terminates prior to the coding region of MRP2 (termed ORF0). uORF6 is also 
in-frame with uORF2 and ORF0. uORF1, 3, 4, and 5 are in the same frame, but 
out-of-frame with ORF0. uORF7 is out-of-frame with both ORF0 and uORF1. 
Among these seven uORFs, uORF1 is unusually long (103 codons) and overlaps 
ORF0. uORF3 and uORF4 share the same stop codon, and the start codon of 
uORF4 is immediately adjacent to the stop codon of uORF5. Therefore, uORF7 
overlaps with uORF6 and uORF5, uORF4 overlaps uORF3 and uORF2, and 
uORF2 overlaps uORF1. The organization of these uORFs is shown in Figure 
4.1.B. 
In the rat Mrp2 5’UTR cDNA sequence, only uORF1 at position -109 among 
all four uORFs is flanked by a perfect Kozak Motif. We have demonstrated in 
Chapter Two and Three that 1) uORF1 exerts an strong inhibitory effect on 
translation; 2) this translational inhibition is not trans-acting; and 3) uORF1 can 
be successfully expressed in the in vitro system [88]. Here, we studied the 
5’UTRs-mediated mechanisms of translational regulation of human MRP2 and 
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focused on the role of uORF2 at position -105 in translational regulation. We 
investigated the effect of the 5’UTRs, particularly the upstream ATGs, on 
translation in the transiently transfected HepG2 cells and in vitro translation. In 
addition, we examined sequence dependence of translational effects exerted by 
uORF2 at position -105. Finally, we also investigated expression of the MRP2 
mRNA isoforms in the liver and HepG2 cells using ribonuclease protection assay.  
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MATERIALS AND METHODS 
Materials 
α-32P-UTP (800 Ci/mmol) was obtained from Perkin Elmer Life and 
Analytical Sciences (Boston, MA). Unless otherwise noted, all other chemicals 
were of analytical grade and of cell culture grade from Sigma Chemical Co. (St. 
Louis, MO), InvitrogenTM Life Technologies (Carlsbad, CA), Roche Diagnostics 
(Indianapolis, IN), and Fisher Scientific (Pittsburgh, PA). Restriction enzymes 
were obtained from Invitrogen, NewEngland Biolab, and Promega (Madison, WI).  
 
Ribonuclease protection assay (RPA) 
Total RNA of the human liver was purchased from Ambion, and total RNA 
from HepG2 cells was isolated using TRIzol (Invitrogen), according to the 
manufacture’s protocol. A fragment of a T7 luciferase vector containing the 
human MRP2 5’UTR sequence was purified from agarose gel after digestion with 
Pvu II and BamH I restriction enzymes. This fragment was used as a template to 
prepare the MRP2 probe by in vitro transcription, and was randomly labeled with 
α-32P-UTP. The RPA was performed following the procedures of the RPA III Kit 
(Ambion). Briefly, total RNA (20 µg) was incubated at -80°C for 90 min with the 
MRP2 probe in the 20 µl mixture containing 0.5 M ammonium acetate plus 2.5 
volumes of ethanol. Following coprecipitation, the RNA pellet was washed once 
with 75% ethanol and dissolved in the hybridization solution (in RPA III Kit). The 
hybridization reaction mixture was incubated at a gradient annealing temperature 
from 56°C to 36°C at a rate of 2°C per 2 hr. After the hybridization reaction, the 
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single-stranded RNA was digested by RNAse A/T1 mix at 37°C for 1 hr. The 
fragments protected from RNAse digestion were identified by electrophoresis on 
6% urea-PAGE gels. 
 
Plasmid construction 
The cDNA sequence of the human MRP2 5’UTR is shown in Figure 4.1.A. 
Schematic representations of the MRP2 5’UTR luciferase fusion constructs are 
shown in Figure 4.3.A. (based on the pGL3 control vector) and Figure 4.4.A. 
(based on the T7 luciferase control vector). All primers are listed in Table 4.1. 
The constructs from the pGL3 control vector were used in transient co-
transfection assays in HepG2 cells. The fragments of Hu-L (-247 nt), Hu-M (-204 
nt), and Hu-S (-99 nt) were cloned into the pGL3 control vector between the 
SV40 promoter and the luciferase coding frame.  
The constructs from the T7 luciferase control vector were used in in vitro 
translation assays. The fragments of hM- and hS- 5’UTR were cloned into the T7 
luciferase control vector at Hind III restriction site between the T7 promoter and 
the luciferase coding region. The plasmid of hmutM was prepared by mutation of 
ATG2 to AAG to disrupt uORF2 using the plasmid of hM as template.  
To determine whether the inhibitory regulation of translation of the ATG2 
is dependent on the amino acid sequence of uORF2, the native sequence from 
position -111 to -1 and the frame-shifted uORF2 sequence were cloned into the 
T7 luciferase control vector. The native sequence from position -111 to -1 was 
PCR-amplified by the pair of primers hF/hR (Table 4.1) using the plasmid Hu-M 
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as template. Both of hF and hR contained a Hind III restriction site. After 
digestion by Hind III, the fragment and the T7 luciferase control vector were 
ligated with T4 ligase, obtaining the plasmid MRP2_22. The plasmid ∆MRP2_22 
was constructed by frame-shifting uORF2 in the plasmid MRP2_h22 through 1) 
deletion of the T at position -101 after ATGG with the primers of hFdel/hRdel; 2) 
insertion of an A before the stop codon TAA at position -39 using the primers 
hFins/hRins; and then 3) disruption of the ATG1 at position -74 by mutation to 
ATA using the primers of hFmut/hRmut. The plasmids h22 and ∆h22 were 
obtained by cloning a spacer sequence from position -143 to -112 between the 
capped site and ATG2 in the plasmids MRP2_22 and ∆MRP2_22, using the pair 
of primers of hFex/hRex, and the pair of primers of ∆hFex/∆hRex, respectively. 
Thus, neither of the plasmids of h22 or ∆h22 contained ATG3 at position -137.  
The luciferase ORF and uORF2 were disrupted in the plasmid h22 by a 
site-directed point mutation with MutLucF/MutLucR and h105aagF/h105aagR, 
respectively, obtaining the plasmids h22_LucAAG and h22_105AAG.  
All mutagenesis was performed according to the manufacturer’s 
instructions of Quick-Change Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA). All the plasmids were confirmed by sequencing. 
 
Transient co-transfection assays in HepG2 cells  
HepG2 cells were cultured in DMEM/F12 (1:1 medium) supplemented with 
10% charcoal-stripped fetal bovine serum (Hyclone Laboratories, Logan, UT), 
3.58 mM glutamine, 55 µg/ml gentamycin, and 1 µg/ml insulin (Invitrogen). One 
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day before transfection, the culture medium was replaced by phenol red-free 
DMEM supplemented with 10% charcoal stripped FBS, glutamine and 
gentamycin. The plasmids (1 µg) (Hu-L, -M, and -S) were transfected by the 
ProFectin mammalian transfection system-calcium phosphate (Promega) into 
HepG2 cells together with 30 ng pSV40-Ren (Promega) used as an internal 
control for transfection efficiency. After 5-6 hr incubation, the transfection medium 
was replaced with the maintenance medium. Cells were harvested 24 hr later for 
measurement of the firefly and Renilla reniformis luciferase activities by the Dual-
luciferase reporter assay system (Promega). The firefly luciferase activity was 
normalized to Renilla reniformis luciferase activity. 
 
In vitro translation assays 
Each of the tested luciferase fusion constructs was linearized by digestion 
with Pvu II and Sac I. The PvuII-SacI fragments of about 1.8 kbp were used as 
templates to prepare luciferase fusion transcripts that were randomly labeled with 
α-32P-UTP. Transcription efficiency was quantified by scintillation counting. Free 
nucleotides in the reaction mixture were washed out by running through 
NucAway™ Spin Columns (Ambion). The luciferase transcripts (0, 2, 4, 10, 20, 
and 40 ng) were added to the reaction mixture and incubated at 30 °C for 60 min. 
The reactions were terminated on ice. The firefly luciferase activity was 
measured by the Luciferase Assay System (Promega) according to the 
manufacturer’s instructions. The lines are the best linear fit of the relationship 
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between luciferase activities and mRNA concentrations whose slopes represent 
translation efficiencies. 
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RESULTS 
Identification of human MRP2 transcription initiation sites in the human 
liver and HepG2 cells by RPA 
Three transcription initiation sites of the human MRP2 gene are reported to 
be located at position -247, -204, and -99 nt relative to the ATG of the human 
MRP2 gene by a study of 5’ rapid amplification of cDNA ends [22] (shown in 
Figure 4.1.A.). The transcription initiation sites and the relative abundance of 
these MRP2 mRNA transcripts were investigated by RPA in the human liver and 
HepG2 cells. All reported transcription initiation sites were detected in the human 
liver and HepG2 cells. The distribution patterns in the liver and HepG2 cells were 
very similar (Figure 4.2.). There were other bands in addition to the reported 
transcription initiation sites, which might also be transcription initiation sites or 
could be degradation products. The transcript with the -247 nt-5’UTR was 
expressed at a very low level in both the liver and HepG2 cells, compared to the -
204 nt- and -99 nt-transcripts, both of which were expressed at a similar level.  
 
Effect of the human MRP2 5’UTRs on expression of the luciferase 
reporter gene in transient cotransfection assays in HepG2 cells 
To investigate the influence of the 5’UTRs of the human MRP2 gene on 
translation, the three 5’UTR sequences (Hu-L, Hu-M, and Hu-S, shown in Figure 
4.3.A.) were fused immediately upstream of the luciferase coding gene in the 
pGL3 control vector. Fusion plasmids were transiently co-transfected individually 
with pSV40-Ren into HepG2 cells. The ratios of the firefly luciferase activity 
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relative to Renilla luciferase activity were normalized to that of the pGL3 control 
vector (the ratio of the pGL3 control vector is one). 
The normalized ratios of the plasmids of Hu-L and Hu-M were 1.16 and 1.23, 
respectively (Figure 4.3.B.), while that of the plasmid of Hu-S was 3.67. Thus, the 
5’UTRs of Hu-L and Hu-M inhibited expression of the luciferase reporter gene 
about 66% in comparison to Hu-S (p<0.001), suggesting the presence of an 
inhibitory element. 
 
Effect of the human MRP2 5’UTRs on the translation efficiency of the 
luciferase transcript in in vitro translation assays 
We investigated the regulatory role of the human MRP2 5’UTRs on 
translation in vitro. The capped luciferase fusion transcripts obtained by in vitro 
transcription contained MRP2 5’UTRs immediately upstream of the luciferase 
ORF (Figure 4.4.A.). The transcripts (0, 2, 4, 10, 20, and 40 ng) were added to 
the rabbit reticulocyte lysate and the reaction mixtures were incubated at 30ºC for 
1 hr. After incubation, the luciferase activity was measured.  
The translation efficiency of hS was 8.2-fold higher than that of hM 
(p<0.0001) (Figure 4.4.B.). The translation efficiency of hmutM containing the 
mutation of ATG2 at position -105 to AAG increased 4.4-fold (p<0.0001), 
compared to that of hM, but was still less than that of hS. 
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Sequence dependence of uORF2 on translation in in vitro translation 
assays.  
Since it was shown that ATG2 exerted an inhibitory effect on translation and 
is flanked by a perfect Kozak motif, we next investigated whether the 
translational inhibition is dependent on the amino acid sequence of uORF2. Two 
plasmids were constructed, one, h22, containing the native amino acid sequence 
of uORF2, and the other, ∆h22, containing the frame-shifted sequence of uORF2 
(Figure 4.5.A.). In vitro transcription-prepared mRNAs from the two plasmids (0, 
2, 4, 10, 20, and 40 ng) were added to the rabbit reticulocyte lysate mixture to 
determine their translational efficiencies.  
Translational efficiency of ∆h22 was only 1.26 times higher than that of h22 
(p=0.002, Figure 4.5.B.) Thus, the inhibitory translation executed by ATG2 is not 
dependent on the amino acid sequence of uORF2 
 
Determining if uORF2 is a cis- or trans-acting regulator on translation 
by in vitro translation assay.  
Using the plasmid of h22 as template, uORF2 in the plasmid h22_105AAG 
and the ORF of the luciferase in the plasmid h22_LucAAG were disrupted, 
respectively, by point mutations of ATG2 at -105 and the ATG of the luciferase 
ORF to AAG. The transcript of h22_LucAAG (0, 2, 4, 10, 20, and 40 ng) was 
incubated with the same amounts (0, 2, 4, 10, 20, and 40 ng, respectively) of the 
transcript of h22_105AAG or T7Luc_ctrl in in vitro translation assays.  
79 
The translation efficiency of the plasmid h22 was 57% of that of T7Luc_ctrl, 
while that of h22_105AAG was 1.12-fold higher than that of T7Luc_ctrl. The 
construct h22_105AAG with disruption of ATG2 increased the translation 
efficiency of h22 2-fold (p<0.0001), bringing it to the level of T7Luc_ctrl. The data 
indicate that uORF2 cis-inhibits translation of the luciferase mRNA. The 
translation efficiency of h22_105AAG incubated together with h22_LucAAG was 
89% of that of h22_105AAG. The presence of h22_LucAAG did not change the 
translation efficiency of h22_105AAG (p=0.1111). The level of T7Luc-ctrl 
translation when incubated with h22_LucAAG was 95% of that when incubated 
without h22_LucAAG. The presence of h22_LucAAG did not change the 
translation efficiency of T7Luc-ctrl (p=0.347). This indicated that h22_LucAAG did 
not exert a trans-acting inhibitory effect on translation (Figure 4.6.). 
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CONCLUSIONS 
First, by means of ribonuclease protection assays (RPA), this study not only 
confirmed (Figure 4.2) the transcription initiation sites at position -247, -204, and 
-99 in the liver and HepG2 cells, but also found that the distribution patterns of 
these sites in the liver and HepG2 cells were similar. The amount of -247 nt was 
much less, compared to -204 and -99 nt. In addition, bands other than the three 
reported sites were also present. Further 5’RACE studies are needed to 
determine if these bands represent transcription initiation sites.  
Second, the upstream uORF2-7 between position -204 and -99 also can 
inhibit translation in transiently cotransfected HepG2 cells either individually or in 
concert ( Figure 4.3), because Hu-S (-99 nt) exhibited a 3.5-fold greater 
luciferase activity relative to Hu-L (-247 nt) and Hu-M (-204 nt). More studies are 
needed to examine their effects. However, uORF2 at position -74 appears not 
play an important role when present alone in hS.  
Third, uORF2 was more critical to the inhibitory effect than other uORFs, 
since it alone contributed about 50% of the inhibitory effect. Deletion of uORF2 
(at position -105) in hM (hmutM) increased translation efficiency 4.4-fold in 
comparison to hM in vitro translation assays (Figure 4.4.). At the same time, the 
translation efficiency of hS was 8.2-fold higher than that of hM.  
Finally, the translation inhibition exerted by uORF2 at position -105 was not 
dependent on the amino acid sequence of the encoded peptide. Furthermore, 
this effect was cis-, not trans-acting. Thus, there was not any difference observed 
in translation efficiency between the native and altered amino acid sequences of 
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uORF2. Further, coincubation of h22_LucAAG in in vitro translation reactions, 
which should express the peptide encoded by uORF2, did not change translation 
efficiency of T7Luc_ctrl or h22_105AAG.  
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FIGURES AND LEGENDS 
 
B  
 
Figure 4.1. The cDNA sequence of the 5’UTR and the schematic 
representation of organization of uORFs of the human MRP2. A. The cDNA 
sequence of the human MRP2 5’UTR. The three transcription initiation sites at 
position -247, -204, and -99 are marked with asterisks. The ATG start codons are 
in bold. The ATG of the MRP2 gene is termed ATG0 and the nucleotides of 
ATG0 are numbered as +1, +2, and +3. Relative to ATG0, the upstream start 
codons at position -74, -105, -137, -146, -173, -180, and -199, are termed ATG1, 
ATG2, ATG3, ATG4, ATG5, ATG6, and ATG7, respectively. Accordingly, the 
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upstream open reading frames of these ATG are named uORF1 -7. The uORFs 
are grey-shaded. uORF1 from position -74 to +234 contains 103 codons; uORF2 
from -105 to -39, 23 codons; uORF3 from -137 to -98, 13 codons; uORF4 from -
146 to -98, 16 codons; uORF5 from -173 to -147, 9 codons; uORF6 from -180 to 
-174, 2 codons; and uORF7 from -199 to -164, 12 codons. B. Schematic 
representation of the organization of the uORFs of the human MRP2. The arrow 
at +1 is the start codon of the human MRP2 mRNA. The rectangles represent the 
uORFs on the MRP2 mRNA strand to scale. The same color filled rectangles are 
in-frame with each other. uORF2 and uORF 6 are in-frame with ORF0; uORF1, 
uORF3, uORF4. uORF5 are all in the same reading frame, but out-of frame with 
ORF0. uORF7 is out-of frame with both ORF0 and with uORF1.  
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Figure 4.2. Detection by RPA of transcription initiation sites of MRP2 and 
their relative abundance in the human liver and HepG2 cells. RNA markers 
(100, 150, 200, and 300 nt) were prepared by in vitro transcription. Probe, 20 µg 
of yeast RNA; human liver RNA, 10 µg; HepG2 cells RNA, 10 µg. The picture is a 
representative of three experiments.  
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Figure 4.3. Effect of the human MRP2 5’UTRs on expression of the 
luciferase gene in HepG2 cells in transient cotransfection assays. A. 
Schematic representation of the MRP2 luciferase constructs used. The inserts (L, 
M, and S) shown were cloned into the pGL3 vector between the SV40 promoter 
and the luciferase ORF. The inserts are shown as the lines to scale. Only ATG2 
is marked. B. The luciferase activity following transient cotransfection assays in 
HepG2 cells. The human MRP2 5’UTR-luciferase constructs were cotransfected 
with pSV40-Ren into HepG2 cells. After 24 hours, the firefly and Renilla 
reniformis luciferase activities were measured. The effect of the 5’UTRs on 
luciferase expression is represented as the ratio of the firefly luciferase activity to 
Renilla reniformis luciferase activity. The assays were performed in triplicate. The 
data are presented as mean ± SEM and normalized to the Luc/Ren ratio of the 
pGL3 control vector. This work was done by Dr. Wei Li in the laboratory. The 
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data were performed One-Way ANOVA and followed with Bonferroni’s pairwise 
comparison.  
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A  
 
B  
 
Figure 4.4. Effect of the human MRP2 5’UTRs on translation efficiency of 
the luciferase transcript by in vitro translation assays. A. Schematic 
representation of MRP2 5’UTR luciferase fusion constructs. The inserts shown 
as the lines to scale were cloned into the T7 luciferase vector between the T7 
promoter and the luciferase ORF. Only ATG2 is marked. B. In vitro translation 
assays. The end-capped, MRP2 5’UTRs-fused luciferase transcripts (0, 2, 4, 10, 
20, and 40 ng) were added to the rabbit reticulocyte lysate mixture. Translation 
reactions were carried out at 30°C for 60 min and then terminated on ice. The 
firefly luciferase activity was measured. The lines are the best fit of the 
relationship between luciferase activities and mRNA concentrations. The slopes 
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represent translation efficiencies. The statistical significance of the difference 
between the slopes was tested by GraphPad Prism 4.0.  
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Figure 4.5. Determination of sequence dependence of uORF2 on translation 
by in vitro translation assays. A. Schematic representation of luciferase fusion 
constructs. The inserts were fused into the T7 luciferase control vector between 
the T7 promoter and the luciferase coding gene. The native sequence from 
position -143 to -1 is shown as the line with the start codons shown as solid bars 
at position -137, -105, and -74 and the stop codon shown as a solid circle at 
position -39. The plasmid h22 was constructed by point mutation of ATG1 at 
position -74 to ATA and deletion of ATG3 at position -137 (open bar) using the 
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plasmid with the native sequence as template. With the purpose of frame-shifting 
uORF2, the plasmid ∆h22 was constructed by deleting T, shown as strikethrough 
(T in ATGGTA), and inserting an A (shown as solid triangle underneath) before 
the stop codon TAA at position -39. B. In vitro translation assays. The capped 
fusion luciferase transcripts obtained by in vitro transcription (0, 2, 4, 10, 20, and 
40 ng) were added to the rabbit reticulocyte lysate reaction mixtures and 
incubated at 30ºC for 1 hr and then terminated on ice. The luciferase activity was 
measured. The lines are the best fit of the linear relationship between luciferase 
activities and mRNA concentrations. The slopes represent translation 
efficiencies. This graph is representative of two experiments. The statistical 
significance of the difference between the slopes was tested by GraphPad Prism 
4.0.  
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Figure 4.6. Determining whether uORF2 acts as a cis- or trans- regulator on 
translation by in vitro translation assay. A. Schematic representation of the 
plasmid constructs. The sequence of position -147 to -1 of the human MRP2 
5’UTR cDNA was inserted at Hind III restriction enzyme site in the T7 luciferase 
control vector (T7Luc_ctrl). The plasmid h22 is the same one shown in Figure 
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4.5. uORF2 was disrupted in the plasmid h22_105AAG by mutation of ATG2 at 
position -105 to AAG, and the ORF of the luciferase in the plasmid h22_LucAAG 
was disrupted by mutation of the ATG of the luciferase gene to AAG. B. In vitro 
translation assays. The transcripts (0, 2, 4, 10, 20, and 40 ng) prepared by in 
vitro transcription were added to the rabbit reticulocyte lysate reaction mixtures 
and incubated at 30ºC for 1 hr and then terminated on ice. The luciferase activity 
was measured. The lines are the best fit of the linear relationship between 
luciferase activities and mRNA concentrations. The slopes represent translation 
efficiencies. The statistical significance of the difference between the slopes was 
tested by GraphPad Prism 4.0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
Table 4.1. Primers used in site-directed mutagenesis for construction of 
human MRP2 5’UTRs fused T7 luciferase vector 
Primers Sequences Constructs 
hF 5’ggacaagcttatcagaatggtagataattcctg3’ 
hR 5’ggtaagcttgattcctggactgcgtc3’ 
MRP2_22 
hFins 5’caacacaatcatatataatagaagagtcttcgttcc3’ 
hRins 5’ggaacgaagactcttctattatatatgattgtgttg3’ 
hFmut 5’cctgttccactttctttgataaaacaagtaaag3’ 
hRmut 5’ctttacttgttttatcaaagaaagtggaacagg3’ 
hFdel 5’ccaagcttatcagaatggagataattcctg3’ 
hRdel 5’caggaattatctccattctgataagcttgg3’ 
∆MRP2_22 
hFex 5’ctcactatagggagacccaagcttgttgggaaaggtcatcc
tttacggagaacatcagaatggtagataattcctgttc3’ 
hRex 5’gaacaggaattatctaccattctgatgttctccgtaaaggat
gacctttcccaacaagcttgggtctccctatagtgag3’ 
h22 
∆hFex 5’ctcactatagggagacccaagcttgttgggaaaggtcatcc
tttacggagaacatcagaatggagataattcctgttc3’ 
∆hRex 5’gaacaggaattatctccattctgatgttctccgtaaaggatg
acctttcccaacaagcttgggtctccctatagtgag3’ 
∆h22 
MutLucF 5’gcccggatccaaaaggaagacgccaaaaac3’ 
MutLucR 5’gtttttggcgtcttccttttggatccgggc3’ 
h22_LucAAG 
h105aagF 5’cctttacggagaacatcagaaaggtagataattcttgttc3’c 
h105aagR 5’ggaacaggaattatctacctttctgatgttctccgtaaagg3’ 
h22_105AAG
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CHAPTER FIVE 
DISCUSSION 
Based on prediction, 30-40% of eukaryotic mRNAs contain uORFs [89], [90]. 
Some uORFs, although not all, serve as important regulatory elements of 
transcript-specific translational regulation [58, 64, 66, 91-95]. Evidence shows 
that expression of both human MRP2 and rat Mrp2 undergo translational 
regulation. Moreover, one of the similarities between Mrp2/MRP2 mRNAs is the 
multiple upstream translation initiation sites present in the 5’UTRs, although the 
human MRP2 mRNA is more complicated in terms of the number of uORFs. The 
studies presented here are focused on the mechanisms by which the uORFs of 
Mrp2/MRP2 regulate translation. Here we discuss the conclusions drawn from 
these studies.  
Before discussion, it is important to point out two considerations in these 
studies. First, because all cellular and most viral mRNAs have 7-
methylguanosine capped (m7G) 5’ ends [54] and translation of mRNAs with 
capped 5’ ends is far more efficient than those without such capped 5’ ends [96], 
the RNAs used in in vitro translation assays all have m7G-capped end structures, 
and were prepared by in vitro transcription using mMESSAGE mMACHINE T7 kit 
(Ambion). Second, we used the luciferase gene, a reporter gene, instead of the 
Mrp2/MRP2 gene, to investigate translational regulation, because the cDNA 
sequences of Mrp2/MRP2 mRNAs are too large (about 4.5 kbp) for efficient 
translation in this in vitro system. 
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ATG1 at position -109 in the rat Mrp2 5’UTR functions as an inhibitory 
element in controlling translation. 
In the rat Mrp2 gene, there are transcription initiates at several different sites 
(position -213, -163, -132, and -98) (Figure 2.1.A.). The existence of the four 
transcripts of Mrp2 mRNA that differ in the length of the 5’UTRs was confirmed 
by RPA in the rat liver (Figure 2.2.). There are four upstream ATGs (ATG1-4 at 
position -109, -149,-197, and -213, respectively) present in the cDNA sequence 
of the longest 5’UTR. Thus, the four mRNA isoforms embrace different numbers 
of upstream ATGs. The ATG4 (at position -213) is in-frame with the Mrp2 ORF, 
while the others are out-of-frame. uORF1 starting at ATG1 (at position -109) 
overlaps the Mrp2 ORF, while the other uORFs terminate prior to the Mrp2 ATG.  
First of all, we investigated the effect of the 5’UTRs on translation by cloning 
the sequences from the 5’ ends to position -1 prior to the ATG of the luciferase 
gene in the luciferase control vector (Figure 2.1.B.). The data in the transiently 
transfected HepG2 cells (Figure 2.3.) indicate that the L (-213 nt), and M1 (-163 
nt) 5’UTRs contain inhibitory elements for expression of the luciferase gene in 
HepG2 cells. But the inhibitory effect is not exerted by the length of the 5’UTRs, 
because the luciferase activities of the luciferase mRNAs containing 5’UTRs of 
La+b (deletion of ATG1 at position -109 termed “a”, and deletion of ATG2 at 
position -149 termed “b”), Lb, M1a+b, and M1b are about the same level as the 
luciferase control mRNA that does not contain any 5’UTR (Figure 2.3.) This is 
consistent with the report that the distance of >1000 nucleotides from the 5’ end 
to the first ATG alone does not reduce the translational efficiency [57]. The data 
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also confirm the results of the analysis of the 5’UTR folding by the computer 
program-mFold: there is not a secondary structure formed in the Mrp2 5’UTRs 
that is stable enough to block ribosome scanning and slow down the translation. 
Another reason supporting the absence of a stable secondary structure is that 
the G+C richness is <50% in the L-, M1-, and M2-5’UTRs. Usually, a long and 
G+C rich 5’UTR will form a stable secondary structure and slow down translation. 
In fact, the translational inhibition is exerted by the upstream ATGs, since 
deletion of the ATGs in L, M1, and M2 increased their luciferase activities both in 
the transfected HepG2 cells and in vitro translation assays. 
To be accurate, it is ATG1, not ATG2, in the Mrp2 5’UTRs that exerts the 
inhibitory effect on translation. There are four, three and two ATGs present in the 
L-, M1-, and M2-5’UTRs, respectively. In the transiently cotransfected HepG2 
cells (Figure 2.4.), the single deletion of ATG1 in the L- and M1-5’UTRs 
abolished the majority of the translational inhibitory effect, increasing the 
luciferase activity almost up to the level of the control luciferase gene (Lb and M1b 
are 80% and 96% of the control). Double deletion of ATG1 and ATG2 just slightly 
changed the luciferase activity (La+b and M1a+b are 93% and 90% of the control, 
respectively), compared to the single deletion. Similarly, in in vitro translation 
assays, a dramatic increase in translation efficiency was observed when ATG1 
was deleted in the L-, M1-, and M2- 5’UTRs (3, 31, and 4-fold higher, 
respectively) (Figure 2.5.B., C., D.), while the single deletion of ATG2 in the M1-
5’UTR only increased translation efficiency slightly (6-fold), and even decreased 
translation efficiency in the L-5’UTR (80%).  
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Therefore, it is obvious that the rat Mrp2 mRNA transcripts with the ATG1-
containing 5’UTRs (L, M1, and M2) would translate much less efficiently than 
those without ATG1 (S1 at position -98, comparison shown by B., C.b., D.c., and 
E.c. in Figure 5.1.). This may partially explain gradually decreasing Mrp2 protein 
expression in the small intestine from jejunum to ileum [48]. Only the S1 (-98 nt) 
and M2 (-132 nt) isoforms are observed in the jejunum and ileum, with the other 
transcripts under detectable limits (Figure 2.2.). However, in the jejunum, the S1 
isoform is expressed at a higher level than the M2 isoform, while in the ileum, 
expression of these two isoforms is reversed. Given the fact that the translation 
efficiency of the S1 isoform is 1.8-fold higher than that of the M2 isoform as 
observed in in vitro translation assays (Figure 2.5.A.), the 9-fold higher 
expression of Mrp2 protein in the jejunum than in the ileum may be explainable. 
Further studies are needed to understand the basis and physiologic implications 
for use of multiple transcription initiation sites by Mrp2, and why their use varies 
among tissues, and to a lesser extent, with age (Figure 2.3.). However, altered 
expression of isoforms is not the reason for the Mrp2 protein changes induced by 
PCN treatment, or pregnancy in rats, because early studies demonstrated that 
use of transcription start sites in the rat liver was not altered by treatment with 
PCN or in pregnancy, implying that this is a fundamental property of the gene 
that is not readily modified [46]. 
In this study, we did not investigate the roles of ATG3 (at position -197) or 
ATG4 (at position -213) in translational regulation. We excluded study ATG4 
because it is the first codon at the 5’ end of the rat Mrp2 mRNA. Ribosomes 
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poorly recognize ATG start codons close to the 5’ end of an mRNA [97], so it is 
unlikely that the 40S subunits and the associated initiation factors could 
recognize ATG4 and initiate translation. The three-codon uORF3 starting at 
ATG3 is much shorter compared to ATG1 and ATG2. Although ATG3 does not 
have a Kozak motif its role in translational regulation should be examined in 
future studies, especially with respect to its interaction with other uORFs. We 
discuss its importance in the following section.  
 
Interaction of uORFs is involved in translation of the rat Mrp2 mRNA.  
We have shown that: 1) ATG1 at position -109 exerts an inhibitory effect on 
translation; and 2) among the four upstream ATGs, only ATG1 has a flanking 
Kozak motif (A at -3, and G at +4 relative to ATG1). We therefore hypothesized 
that ATG1 is able to be recognized efficiently by scanning ribosomes so that 
uORF1 is translated, according to the scanning model. This hypothesis is 
confirmed by two experiments in the transcription/translation coupled system. 
First, a longer luciferase protein (with higher molecular weight) was observed 
when ATG1 was in-frame with the luciferase ORF in the deL and deM1 (Figure 
2.6.). In this same experiment, deletion of ATG1 (deLb and deM1b) or the 
absence of ATG1 (S2) abolished expression of the longer luciferase molecule. 
Second, expression of Pep56 encoded by uORF1 was observed when the 
pcDNA3.1 vector containing uORF1 was expressed in the TnT system (Figure 
3.4.).  
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Thus, the inhibitory effect exerted by ATG1 on translation of a downstream 
cistron is due to the fact that only a portion of the scanning ribosomes translate 
downstream luciferase in vitro or Mrp2 in vivo, while other ribosomes translate 
uORF1 when the scanning ribosomes encounter ATG1. Both in the luciferase 
fusion vector and the Mrp2 gene, uORF1 terminates within the downstream 
ORFs. It is known that scanning ribosomes are unable to jump backward to 
reinitiate at an upstream start codon after translating an uORF [58, 98, 99]. 
Therefore, it is impossible for scanning ribosomes to reinitiate at ORFs of the 
luciferase or Mrp2 after translating uORF1. The mechanism of ATG1 modulating 
expression of both the luciferase and rat Mrp2 mRNA must therefore be a leaky 
scanning model (shown by C.a., D.a., and L.a. in Figure5.1.) 
There are two mechanisms that could explain the fact that uORF2 (starting 
at ATG2 at -149) or uORF3 (ATG3 at -197) only exert a minor inhibitory effect on 
translation of a downstream main ORF (like luciferase mRNA in vitro, and the 
Mrp2 mRNA in vivo). First, with respect to the leaky scanning model, since 
neither ATG2 nor ATG3 has a Kozak motif, the association affinity of ATG2 or 
ATG3 with the scanning ribosomes is weak, leading to their being bypassed by 
scanning ribosomes. Second, with respect to the reinitiating model, the scanning 
ribosomes reinitiate translation more efficiently when there is a longer distance 
between the termination codon of a uORF and the next start codon. This occurs 
because the 40S ribosomal subunits still associated with the mRNA strand after 
translating the uORF are believed to have enough time to recruit again the 
required translation initiation factors [98, 99]. When the intercistronic space is 
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lengthened from 16 to 64 nucleotides, reinitiation efficiency increases from 16% 
to 38% [100]. The distances from the termination codons of uORF2 at position -
149 and uORF3 at position -197 to ATG0 are 123 and 187 nucleotides, 
respectively, both of which should be sufficient for the scanning ribosomes to 
fully reinitiate at ATG0. Either of these two mechanisms leads to only a minor 
inhibitory effect of uORF2 and -3 on translation of the downstream cistron (shown 
by D.b. and E.b. in Figure 5.1.).  
However, the interaction of ATG2 at position -149 or ATG3 at position -197 
with ATG1 may be of importance in terms of exerting a translational regulatory 
effect. The sequence distances from the termination sites of uORF2 and uORF3 
to ATG1 at position -109 are 13 and 79 nucleotides, respectively. Obviously, the 
13-nucleotide space is not long enough for ribosomes to reinitiate efficiently at 
ATG1 if uORF2 is translated, even with poor efficiency. However, because of the 
space of 79 nucleotides between the termination site of uORF3 and ATG1, 
reinitiation at uORF1 is efficient after ribosomes translate uORF3. Therefore, 
uORF1 and ORF0 could be competitors for the reinitiation scanning ribosomes, 
but this competition depends on whether uORF2 or -3 is translated. A proposed 
mechanism is that when translation of uORF2 occurs, the scanning ribosomes 
bypass uORF1 and reinitiate at ORF0; when uORF3 is translated and uORF2 is 
bypassed, reinitiation occurs at uORF1, not ORF0, resulting in inhibitory 
translation of ORF0. Therefore, uORF2 could be an activator or repressor of 
translation of the downstream main ORF, depending on whether or not it is 
translated.   
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The distance between the cap site and the initiation codon is very important 
for recognition of a uORF by 40S subunits. A study of mammalian S-
adenosylmethionine de-carboxylase (AdoMetDC) shows that recognition of the 
single uORF in the AdoMetDC 5’UTR in nonlymphoid cells is increased by 
extending the space between the cap site and the upstream ATG codon from 14 
to 47 nucleotides, leading to suppression of translation of AdoMetDC.[101]. The 
order of translation efficiencies of the 5’UTRs in Mrp2 from high to low are S1 (-
98 nt), M2 (-132 nt), L (-213 nt), and M1 (-163 nt) (Figure 2.5.A.). That translation 
of S1 is faster than any other one is because S1 does not contain any uORF and 
the full complement of scanning ribosomes recognizes ORF0. When the space 
prior to the ATG2 at position -149 is shortened from 64 nucleotides in L to 14 
nucleotides in M1, recognition of uORF2 by the scanning ribosomes in L is more 
efficient than that in M1. Thus when translation of uORF2 occurs in L, reinitiation 
is not able to occur at uORF1 because of the short intercistronic space of 13 
nucleotides, but occurs at ORF0. In contrast, in M1, ribosomes bypass uORF2, 
and translation of uORF1 occurs, suppressing the translation of ORF0. This 
provides a likely explanation for why translation efficiency of the luciferase 
transcript containing L is 15-fold higher than that of M1. Therefore, in terms of 
translation of ORF0, uORF2 functions as an activator in L, but an inhibitor in M1, 
which explains two observations in the in vitro translation assays: 1) deletion of 
ATG2 at position -149 of La decreased translation efficiency 80% compared to L, 
while 2) deletion of ATG2 of M1a increased translation efficiency 6-fold compared 
to M1.  
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The distances prior to ATG1 at position -109 in the L (-213 nt), M1 (-163 nt), 
and M2 (-132 nt) 5’UTRs are 104, 54, and 23 nucleotides, respectively. 
Therefore, recognition of uORF1 is less efficient in M2 than that in L and M1 
(shown by the comparison of C.a. and D.a. in Figure 5.1.), resulting in the 
increase of translation of ORF0 in M2, compared to L and M1, which explains 
why translation efficiency of M2 is higher than that of L and M1.  
Together, the mechanisms of uORFs-mediated translational regulation in the 
S1 (-98 nt), M2 (-132 nt), M1 (-163 nt) and L (-213 nt) transcripts are the 
combination of the leaky scanning model and reinitiation model. That is, 
interaction of the uORFs influences translation of the downstream main ORF. 
This kind of interaction depends on the intercistronic distances and the distances 
between the 5’ end and start codons of uORFs. The schematic representation of 
this mechanic model is shown in Figure 5.1. 
We already showed that translation of uORF1 in in vitro systems and 
transiently cotransfected HepG2 cells contributes the majority of translational 
inhibition. Future studies should focus on the effect of interactions between these 
uORFs on translation. Thus, do PCN treatment or pregnancy selectively affect 
translation of alternative uORFs in the Mrp2 5’UTRs, thus changing Mrp2 protein 
expression? The studies on factors controlling GCN4 translation show that the 
level of the active form of eIF2 selectively determines the use of uORFs in amino 
acid-rich or -deprived medium. Future studies should investigate the eIF2 level in 
relation to the use of Mrp2 uORFs in PCN-treated vs pregnant rats.  
103 
Finally, the MDM2 transcript has two forms differing in the 5’UTRs: a long 
form (L-mdm2) which contains two uORFs, and a short form (S-mdm2) without 
uORFs. Brown and Morris reported that overexpression of MDM2 observed in 
some tumor cells is related to the elevated ratio of S-mdm2 to L-mdm2. Also, by 
using sucrose gradient ultracentrifugation to ascertain the extent of ribosome 
loading on specific mRNA species, they found that L-mdm2 is loaded with 
ribosomes inefficiently in comparison with S-mdm2 [102]. However, in our case, 
Jones et. al [46] reported that the relative abundance of the four isoforms of the 
hepatic Mrp2 mRNA is not altered in PCN-treated, pregnant, and control rats. 
However, they showed that more Mrp2 mRNAs are loaded with polysomes 
following PCN treatment than vehicle treatment of the rats. When we 
ultracentrifuged the total RNAs from the PCN-treated rat liver in sucrose 
gradients and analyzed by RPA the fractions from these gradients, we did not 
find an altered relative abundance of these Mrp2 transcript isoforms in each 
gradient (data not shown). Therefore, the mechanism of Mrp2 translational 
regulation mediated by uORFs is different from that of MDM2.  
 
uORF1 in controlling translation of the Mrp2 is not a trans-acting 
factor.   
As pointed out by Morris [22, 64], nascent peptides encoded by uORFs can 
mediate regulation through interfering with translation elongation or termination. 
Ribosomes stall and translation of the downstream ORF is inhibited. These 
mechanisms are supported by identification of the active roles of the peptide 
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products of various prokaryotic and eukaryotic uORFs in translational control 
[103, 104]. The amino acid sequence-dependence of the uORF-encoded 
peptides has been confirmed in several genes, including AdoMeDC, CPA1, and 
arg-2, although no conserved amino acids have been found across species or 
genes [64].  
As a major inhibitor among all four uORFs in controlling rat Mrp2 translation 
and with a perfect flanking Kozak motif, uORF1 was hypothesized to stall 
ribosomes by association of the nascent encoded peptide with the scanning 
ribosomes, that is, by an amino acid sequence-dependent mechanism. Efficient 
translation of uORF1 was confirmed by observing a higher molecular weight of 
luciferase expressed in the TnT system when uORF1 was in-frame with the 
luciferase gene (Figure 2.6.). Further, the encoded peptide product, Pep56 
(MW=6.5 kDa), was also expressed in the TnT system (Figure 3.4.). 
To investigate the amino acid-sequence dependence of inhibition of 
translation, uORF1 was cloned prior to the luciferase ATG, not overlapping its 
ORF. The Kozak motif sequence flanking ATG1 in the Mrp2 mRNA was 
maintained in all tested luciferase fusion vectors. In order to guarantee that 
reinitiation is fully able to occur at the luciferase ATG, a spacer sequence (from 
position +62 to +92) was cloned into the vectors. Thus, the distance between the 
uORF1 termination codon and the luciferase start codon is 71 nucleotides, 
including the spacer sequence in the control vector. Frame-shifting was used to 
create a different amino acid sequence, considering 1) the 56 amino acids of 
uORF1 are too many to mutate one by one, and 2) to keep the nucleotide 
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sequence unchanged to avoid any effect that the altered nucleotides might have 
on transcription or mRNA processing (Figure 3.1.).  
There was no difference observed in translation efficiency between the 
native and altered amino acid sequences (r56 and ∆r56, respectively, Figure 
3.2.E.), but both inhibited translation compared to the luciferase control vector. In 
addition, deletion of ATG1 at position -109 in r56 did not change translation 
efficiency (data not shown). Therefore, the translational inhibition by uORF1 in 
r56 and ∆r56 is because of the existence of ATG0 (at position +1) of Mrp2, which 
is a perfect translation initiation site. This may obscure the effect of amino acid-
sequence dependence. Another explanation may be the amino acid similarity 
between the native and altered forms, because there is not a large difference in 
their PI values (9.6 for the native, 11.4 for the scrambled). The presence of ATG0 
may also explain the difference in translation efficiency of the first (rF), second 
(rM) and third (rL) 22 amino acid segments, because the second and third 
segments included ATG0, while the first did not (Figure 3.2.A.). However, the 
altered sequences of ∆rL and ∆rM dramatically increased translation efficiency in 
comparison to their native sequences, rL and rM, respectively (Figure 3.2.B and 
C.). We could not narrow down the amino acids that play the critical roles in the 
sequence dependence, since no differences in translation efficiency were 
observed between r11_1, _2, and _3 (Figure 3.2.D.). We propose that all the 
amino acids in the segment without the first 22 amino acids work together in 
controlling translation. Future studies should investigate whether ribosome 
stalling occurs at elongation or termination steps, and how.  
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However, we determined that association of the amino acids encoded by 
uORF1 with the scanning ribosomes is cis-, not trans-acting, since the translation 
efficiencies of the luciferase mRNAs did not differ when T7Luc_ctrl was 
incubated alone or when it was incubated under conditions where the peptide 
encoded by uORF1 in r56_LucAAG could be translated (Figure 3.3.B.). 
Moreover, addition of the commercially synthesized peptides of the second or 
third segments (r11aa_2 and r11aa_3) into in vitro translation reactions did not 
change translation efficiency of the control luciferase transcript (data not shown). 
Although the peptide encoded by uORF1 was expressed in the TnT system 
(Figure 3.4.), we could not detect its expression by immunoblotting analysis in 
the rat liver or kidney tissues (shown in Figure 3.5., and 3.6.). These data 
suggest that the peptide is rapidly degraded in vivo. Finally, following transient or 
stable transfection of HepG2 cells with the pcDNA3.1 vectors containing uORF1, 
the peptide could not be detected in the cell extracts (data not shown).  
 
The mechanisms involved in controlling translation of the human 
MRP2 mRNA mediated by 5’UTRs  
The data in transiently cotransfected HepG2 cells suggest that the upstream 
uORF2-7 between position -204 and -99 inhibit expression of the luciferase. The 
luciferase expression levels of Hu-L (-247 nt) and Hu-M (-204 nt) were the same 
because there are not any upstream ATGs between position -247 and -204 
(Figure 4.3.). Interestingly, the luciferase activities of Hu-L and -M are similar to 
that of the control luciferase that does not contain any 5’UTR, indicating that the 
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differing lengths of Hu-L (-247 nt) and Hu-M (-204 nt) 5’UTRs do not affect 
translation. This is consistent with the observation in the rat Mrp2 5’UTR that the 
length of the 5’UTRs has no effect on translation. These data also suggest that 
there are not stable secondary structures in Hu-L or Hu-M 5’UTRs (Figure 4.4.).  
The translational inhibitory role of uORF2-7 is also true in in vitro translation 
assays. However, by point mutation of ATG2 at position -105 to AAG, we found 
that among these uORFs, uORF2 at position -105 is the major player in inhibition 
of translation, which alone contributes about 50% of the inhibitory effect, with the 
other uORFs contributing the other 50% of the translational inhibition. This is 
because among all uORFs, uORF2 is the only one that has a perfect Kozak 
Motif. Even the sequence flanking the ORF of human MRP2 is not a perfect 
Kozak Motif. Therefore, according to the scanning model of translation, the 
scanning ribosomes can efficiently recognize ATG2 at position -105 and initiate 
translation of uORF2, resulting in down-regulation of translation of the 
downstream main ORF, the luciferase ORF in vitro or the MRP2 ORF in vivo, by 
either the leaky scanning model or the reinitiation model. The effect of the other 
uORFs and their interactions on translation should be investigated in future 
studies.  
Interestingly, translation efficiency of hS (-99 nt) was higher than that of 
T7Luc_ctrl in in vitro translation assays, consistent with what was observed with 
Hu-S in transfected HepG2 cells. This suggests 1) the presence of a translational 
active element between position -99 to -1; 2) uORF1 at position -74 in hS (-99 nt) 
does not inhibit translation. Given the fact that uORF1 at position -74 is unusually 
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long and overlaps with the human MRP2 coding gene, the fact that uORF1 does 
not affect translation of the luciferase is in contrast to the current model in which 
a uORF overlapping the downstream main ORF suppresses translation of the 
downstream cistron, because no reinitiation occurs or only a portion of the 
ribosomes (the leaky scanning model) initiate at the downstream ORF. However, 
in the hS (-99 nt) 5’UTR, the distance between the capped end to ATG1 (-74 nt) 
is 25 nucleotides, which may not be long enough for the scanning ribosomes to 
efficiently recognize ATG1, which also does not have a perfect Kozak Motif. This 
may explain why ATG1 in the hS has no inhibitory effect on translation of the 
luciferase. Future studies should investigate the translational regulatory role of 
ATG1 at position -74 in hL (-247 nt) and hM (-204 nt), because the distances 
between the capped ends of these two 5’UTRs and ATG1 should be long enough 
for the scanning ribosomes to initiate translation of uORF1 if ATG1 is recognized.  
The inhibitory effect exerted by uROF2 at position -105 on translation is not 
dependent on the encoded nascent 22-amino acid peptide (Figure 4.5.). Further, 
there was no trans-acting effect of uORF2 observed on translation in in vitro 
translation assays (Figure 4.6.). Finally, the peptide could not be detected when 
expressed in the transcription/translation coupled system with 35S-Methionine to 
label the newly synthesized peptide (data not shown). Addition of the 
commercially synthesized peptide into in vitro translation reactions did not 
change translation efficiency of T7Luc_ctrl (data not shown). Expression of 
MRP2 protein did not change in transiently or stably transfected HepG2 cells with 
a pcDNA3.1 vector containing uORF2 (data not shown). In addition, treatment of 
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HepG2 cells with the synthesized peptide did not change MRP2 expression (data 
not shown). Therefore, we propose that uORF2 is a cis-acting repressor of 
translation by the mechanism of leaky scanning and reinitiation.  
Future studies should investigate the roles of the individual uORFs and their 
interactions in translational regulation.   
 
Speculations 
First, this research provides a framework to understand translational 
regulation of human MRP2 and rat Mrp2 that could occur under certain 
conditions (pregnancy, cholestasis, cancer, etc.), i.e., uORF-mediated 
translational regulatory mechanisms. It was shown in in vitro systems that rat 
uORF1 at position -109 and human uORF2 at position -105 are translational 
inhibitors. Both the leaky scanning and the reinitiation model are involved in the 
rat uORFs-mediated mechanisms of translational regulation. Therefore, under 
certain conditions (pregnancy, cholestasis, cancers), translation of hepatic 
human MRP2 and rat Mrp2 mRNAs are proposed to be regulated by selective 
translation of the different uORFs, thus affecting reinitiation or leaky scanning of 
the downstream ORFs. The level of eIF2 has been shown to affect selective 
translation of uORFs in the translational regulatory model of GCN. Future studies 
should identify the eIF2 expression levels in PCN-treated and pregnant rats and 
its correlation with selection of uORFs.  
Second, more sensitive methodology should be used to detect expression of 
Pep56 in the rat liver and kidney. Proteomic analysis [73] found four novel small 
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peptides encoded by uORFs in human leukemia K562 cells by direct nanoflow 
liquid chromatography (LC) coupled with the electrospray ionization (ESI)-
tandem mass spectrometry (MS/MS) system. This investigation provides the first 
direct evidence of translation of upstream open reading frames in human cells 
[73]. In this research, the antibody to Pep56, PAS, failed to detect Pep56 in the 
rat liver and kidney, although PAS successfully detected the positive control of 
Pep56, Pep56-His. In the future, small peptides should be separated and 
concentrated from the rat liver or kidney homogenate by SDS-PAGE separation, 
acid extraction, or immunoprecipitation by PAS and then nanoflow LC coupled 
with ESI-MS/MS should be used to detect Pep56.  
 
Physiological and clinical significances  
The human MRP2 protein plays an important role in the pharmacokinetics 
and toxicity of its substrate drugs, because it is localized on the apical 
membranes of cells of the liver, kidney, small intestine, and brain, and thus 
affects absorption, disposition, and elimination of the drugs. Some anti-cancer 
drugs are substrates for human MRP2, including cisplatin, paclitaxel, 
doxorubicin, vinblastine, sulfinpyrazone, irinotecan SN38, and methotrexate 
[105]. Changes in MRP2 protein expression may affect transport and/or 
pharmacokinetics of these substrates. Also, some anti-cancer drugs induce drug-
resistance by increasing MRP2 expression. For instance, chemotherapeutic 
treatment with doxorubicin increases human MRP2 expression in recurrent and 
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residual tumors of the bladder in comparison with that in untreated primary 
tumors [106].  
Moreover, human MRP2 protein expression differs in normal and tumor 
tissues. MRP2 protein is expressed at a lower level in the cancerous renal cortex 
than in the normal cortex [107]. Analysis of regulation of the hamster pgp1 
homologue found that transcription initiates at a single site in drug-sensitive cells, 
while drug-resistance cells utilize several downstream initiation sites [108-110]. 
Multiple transcription initiation sites are also present in the human MRP2 gene in 
the liver (shown in Chapter Four) and placenta [22]. We have shown that the 
relative abundance of the three MRP2 transcription initiation sites (at position -
247, -204, and -99) is similar in the normal liver and HepG2 cells, with -204 nt 
and -99 nt being the major two sites. But, does transcription of the MRP2 gene 
utilize the same initiation sites in cancerous tissues as in normal tissues, or is 
each initiation site equally used? The MRP2 transcript containing the -99 nt 
5’UTR (termed hS in Chapter Four) translates much faster than the other two 
transcripts containing -204 nt and -247 nt 5’UTRs (termed hM and hL). 
Therefore, the relative abundance of the three MRP2 transcripts in tumor tissues 
may differ from that in the normal tissues, or be regulated by anti-cancer drugs, 
thus leading to regulation of MRP2 protein expression at the translation level. 
Future investigation should address these issues by RPA.  
Interindividual pharmacokinetic variability of anticancer agents is a problem 
in chemotherapy. Genetic polymorphisms of the MRP2 gene are one of the 
factors influencing interindividual pharmacokinetic variability in chemotherapy. 
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The human MRP2 gene is shown to have more than 200 naturally occurring 
mutations. The single nucleotide change at -24C→T is in the 5’UTR [111]. The 
exchange of -24C→T has been demonstrated to be associated with lower MRP2 
mRNA expression in non-cancerous renal cortex tissues compared to that in 
unaffected tissues [86].  Analysis of organization of the MRP2 uORFs (Figure 
4.1) shows that -24C is located in uORF1 of all seven uORFs, and -24C→T is a 
synonymous mutation for uORF1. Future studies should examine the effect of 
this single nucleotide polymorphism (SNP) on translation. By in vitro assays and 
transient transfection assays in HepG2 cells, translation efficiency of the 
transcripts containing -204 nt 5’UTRs should be compared with that of its mutant 
containing the exchange of -24C→T. The same experiments should also be done 
with the transcript containing -99 nt 5’UTR and its mutant of -24C→T.  
Therefore, investigation of the mechanisms underlying translational 
regulation of the human MRP2 expression likely provides an additional 
perspective from which to understand the drug resistance and interindividual 
variability in chemotherapy in which the human MRP2 protein is involved.  
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FIGURE AND LEGEND 
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Figure 5.1. A hypothetical mechanistic model of uORFs-mediated 
translational regulation of the rat Mrp2 mRNA. The percentages of the 
scanning ribosomes labeled above that initiate translation are predicted values 
calculated from the data in in vitro translation assays.  A. The schematic 
representation of organization of uORFs of the rat Mrp2 mRNA. The strand of rat 
Mrp2 mRNA is represented as a bold line and its start codon is shown as an 
arrow at position +1. Positions of the start codon and termination codon of each 
uORF shown as grey rectangles are labeled. B. Since there is not any uORF 
present in the S1 (-98 nt) transcript, 100% of the scanning ribosomes initiate 
translation of ORF0 at +1 in the -98 nt transcript.  C. In the M2 (-132 nt) 
transcript, only uORF1 is present. a. About 75% of the scanning ribosomes 
initiate translation of uORF1 by leaky scanning ORF1. b. About 25% of the 
scanning ribosomes initiate translation of ORF0 by leaky scanning all of uORFs. 
D. Both of uORF1 and uORF2 are present in the M1 (-163 nt) transcript. a. About 
82% of the scanning ribosomes initiate translation of uORF1, which is more than 
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75% in the M2 (-132 nt) transcript, because the distance of 54 nucleotides from 
the 5’ end to the start codon is longer than that in the M2 transcript (23 
nucleotides). b. About 15% of the scanning ribosomes initiate translation of 
uORF2. The distance of -123 nucleotides between the termination codon of 
uORF2 and the start codon of ORF0 is enough for at least a portion of the 
ribosomes to reinitiate translation of ORF0. c. About 3% of the scanning 
ribosomes initiate translation of ORF0 by leaky scanning all of uORFs. E. All 
uORF1-4 are present in the L (-213 nt) transcript. a. After encountering uORF2-4, 
fewer scanning ribosomes (about 70%) initiate translation of uORF1, compared 
to that in the M1 (-163 nt) transcript (82%). b. About 20% of the scanning 
ribosomes initiate translation of uORF2 and then reinitiate translation of ORF0. c. 
About 10% of the scanning ribosomes initiate translation of ORF0.   
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Appendix A 
 
List of abbreviations 
2-AAF 2-acetylaminofluorene  
AdoMetDC S-Adenosylmethionine decarboxylase  
AP1 Activator protein 1  
C/EBPα CCAAT-enhancer binding protein α  
CAR Constitutive androstane receptor 
CBF C-repeat binding factor  
CCRCC Clear-cell renal cell cancer  
cDNA Complementary deoxyribonucleic acid 
CMV Cytomegalovirus  
DBcAMP Dibutyryl-cyclic AMP 
E217G Estradiol-17β-D-glucuronide  
EE2  Ethinylestradiol 
EFIA Enhancer factor IA  
ER-8 Everted repeat with 8 bp spacer  
FBS Fetal bovine serum 
FXR Farnesoid X-activated receptor 
GRE Glucocorticoid-responsive element  
GSH Glutathione 
HNF1 Hepatic nuclear factor 1 
IRF3 Interferon regulatory factor  
ISRE Interferon stimulatory response element  
LPS Lipopolysaccharide 
m7G 7-methylguanosine  
mRNA  Messenger ribonucleic acid 
Mrp2/MRP2 Multidrug resistance-associated protein 2 
MSD Membrane-spanning domain 
MW Molecular weight 
NBD Nucleotide binding domain 
PBS Phosphate buffered saline 
PCN  Pregnenolone-16α-carbonitrile 
PCR Polymerase chain reaction 
PEA3 Polyomavirus enhancer A binding protein-3  
PPRE Peroxisome proliferators responsive element 
PXR Pregnane X receptor  
RARβ2 Retinoic acid receptor-β2  
RPA Ribonuclease protection assay 
RXRα Retinoid X receptor α 
SDS Sodium dodecyle sulfate 
SNP Single nucleotide polymorphism  
Sp1 Specificity proteins  
uORF Upstream open reading frame 
USF Upstream stimulatory factor  
UTR Untranslated region 
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Appendix B 
 
Ribonuclease Protection Assay (RPA) (RPA III Kit, Ambion, Austin) 
 
1. Preparation of the radio-labeled probe (MAXIsript Kit) 
 
a. The vector containing the probe sequence is digested with the restriction 
enzymes PvuII and BamH I and separated by electrophoresis on 2% agarose 
gel. A double-stranded 280 bp fragment containing the T7 promoter and the 
probe sequence is purified using Qiaquick Gel Extraction Kit (Qiagen) and 
concentrated by vacuum centrifugation at 60ºC. This is the DNA template for in 
vitro transcription reaction.  
b. Vortex the reaction buffer and nucleotide solutions until they melt. Keep 
the reaction buffer at room temperature and nucleotide solutions on ice.  
c. Assemble the in vitro transcription reaction mix in 0.5 ml tubes at room 
temperature as following:  
 
Reagents Volume 
DNA template                                       5 µl
10x reaction buffer 2 µl
10 mM ATP 1 µl
10 mM GTP                                           1 µl
10 mM CTP 1 µl
α-32P-UTP (800 Ci/mmol, 10 mCi/ml) 5 µl 
Enzyme Mix 2 µl
DEPC-treated Water 3 µl
Total volume 20 µl 
 
d. Mix well by flicking the tube or pipetting the mix up and down, and 
centrifuge briefly to collect all reagents at the bottom.  
e. Incubate the reaction mix at 37ºC for 10 min.  
f. Add 1 µl DNAse I and incubate at 37ºC for 15 min 
g. Add 1 µl 0.5 M EDTA solution and 22 µl loading dye, and then incubate at 
95ºC for 3 min.  
h. Before loading samples on 6% urea-PAGE gel (Invitrogen), pre-run the gel 
for 30 min and rinse the wells.  
i. Load the sample on the gel and keep running in 1x TBE running buffer at 
150 V until the bromophenol blue approaches the bottom of the gel.  
j. Take down the gel and carefully separate the plastic plates. The gel will 
stick to one plate.  
k. Cover the gel side with plastic film and wrap the plastic plate 
l. Expose the gel to X-ray film with the gel side facing the film. (Note: make 
sure that it is possible to re-position the gel and film after film development.) 
m. Overlap the film and the gel in exactly the same manner as during 
exposure and mark the band of the probe on the plastic plate.  
n. Unwrap the gel and cut out the marked band.  
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o. Put the gel band in 350 µl elution buffer (RPA III Kit), shred the gel band, 
and leave it in the hood at room temperature overnight. Do not need to centrifuge 
to recover the supernatant.  
p. 1-2 µl of the elution solution is used for RPA incubation with total RNA.  
 
2. Preparation of the radio-labeled RNA ladders (MAXIscript Kit, Austin) 
 
a. PCR amplification of the DNA templates for the RNA ladder preparation  
Assemble the PCR reaction mix as following using (Clontech Advantage 2 PCR 
Kit) 
 
Reagents Volume 
10X reaction buffer    5 µl 
DNA template (Vector T7-Toe1)         1 µl 
Forward primer (T7 promoter) (10 µM)        1 µl 
Reverse primer (R100, R150, or R200) (10 
µM)       
1 µl 
50x dNTPs           1 µl  
Taq polymerase 1 µl 
DEPC-treated water 40 µl  
Mineral oil 30 µl 
Total Volume 50 µl 
The first reaction is performed as following:  
Step:   1) 95°C for 2 min 
           2) 95°C for 20 sec 
           3) 52°C for 20 sec 
           4) 72°C for 20 sec 
Repeat step 2 to 4 33 times and perform a 5- min elongation reaction.  
 
b. The PCR product is separated on 2% agarose gel, purified using Qiaquick 
Gel extraction Kit (Qiagen), and concentrated by vacuum centrifugation at 60ºC 
using Vacuumed (Eppendorf).  
c. Assemble the reaction mix for in vitro translation as following:  
Reagents Volume 
DNA templates: 
   T100 
   T150 
   T200                                                   
 
                3 µl  
2 µl 
2 µl 
10x reaction buffer 2 µl 
10 mM ATP 1 µl 
10 mM GTP                                           1 µl 
10 mM CTP 1 µl 
0.5 mM UTP 1 µl 
α-32P-UTP (800 Ci/mmol, 10 mCi/ml) 5 µl  
Enzyme Mix 2 µl 
Total volume 20 µl 
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d. Flick the tube and mix well, and then spin briefly.  
e. Incubate the reaction at 37ºC for 1 hr.  
f. Add 1 µl DNAse I and incubate at 37ºC for 15 min. 
g. Add 1 µl of 0.5 M EDTA (pH8.0) and 22 µl of loading dye, and then 
incubate at 95ºC for 3 min 
h. Load the sample on 6% urea-PAGE gel to check the quality of the probe. 
Usually it is good enough to use directly without gel purification.  
 
3. Ribonuclease protection reaction.  
 
a. Assemble the reaction as following on ice 
 
Reagents Volume 
Total RNA    20 µg
Radio-labeled probe    1-2 µl
NH4Ac (5M)         1 µl
 
Bring up the total volume of reaction to 50 µl with DEPC-treated water. And add 
125 µl (2.5 x volumes) ethanol.  
 
b. Vortex and mix well. Store the reaction at -80ºC for at least 2 hr 
c. Precipitate the RNA by centrifugation at maximum speed for 30 min at 4ºC 
and carefully remove the supernatant.  
d. Wash the RNA pellet one with 250 µl of 70% ethanol in DEPC-treated 
water. Carefully remove the supernatant without touching the pellet. Do not use 
the 1 ml tips which might suck up the pellet.  
e. Spin the tubes after washing and remove the residue of supernatant with 
10 µl tips.  
f. Add 10 µl Hybridization buffer (RPA III) and pipette up and down to 
resuspend the RNA pellet.  
g. Denature the reaction mix by incubation at 93ºC for 3 min.  
h. Incubate the reaction mix at decreasing temperature from 56ºC to 36ºC at 
the rate of 2ºC per 2 hr per step. Set the final step at 4ºC to keep the reaction mix 
chilled until the next step after incubation. It takes overnight to finish the 
incubation.  
i. Next day, add 150 µl of diluted RNAse mix (1:100) into the reaction mix, 
and incubate at 37ºC for 1 hr to digest the single stranded RNA.  
j. Stop the reaction by adding 225 µl of RNAse Inactivation & Precipitation 
Buffer. And then add 2 µl of carrier RNA (1 µg/µl), and 75 µl ethanol.  
k. Vortex and mix well the reaction mix. Store at -80ºC for at least 1 hr.  
q. Precipitate the RNA by centrifugation at maximum speed for 30 min at 
4ºC. There is a tiny blue RNA pellet at the bottom of the tube. Carefully remove 
the supernatant without touching the pellet.  
r. Spin the tube again to collect and carefully remove the residue of 
supernatant.  
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s. Resuspend the RNA pellet in 15 µl loading dye. Denature RNA at 95ºC for 
3 min, and then the samples are ready for loading on 6% urea-PAGE. 
  
4. Cast 6% urea-PAGE gel before taking out the reactions from incubation,  
 
a. Set up the gel cassette. Two glass plates (size: 16x19.7 cm, and 19x19.7 
cm) are washed by detergent and the insides wiped with Methanol. Let them air 
dry. Then wipe inside of the big plate with Sigmacote and dry in the hood (Note: 
Sigmacote is toxic and volatile, so the operation should be in the hood). The 
thickness of two side spacers and one bottom spacer used is 0.5 mm. The two 
plates are clipped together tightly with big binder clips on both sides and bottom.  
b. Reagents, buffers and gel casting 
 
10xTBE buffer 
 
Tris-base 110 g
Boric acid  55 g
EDTA 5.8 g
 
Dissolve in 1L DEPC-treated water.  
 
30% Acrylamide : Bis Mix (19:1) 
 
Acrylamide  150 g
N.N‘-Bis-methylene Acrylamide  4 g
   
Bring up to 500 ml with DEPC-treated water 
Filter and store at 4ºC.  
            
6% urea-PAGE gel   
 
Urea 12 g 
10X TBE 2.5 ml
30% Acrylamide: Bis Mix (19:1) 5 ml
H2O 8 ml
TEMED  15 µl
10% ammonium persulfate 200 µl 
 
Before adding TEMED and 10% ammonium persulfate, stir at room temperature 
till urea is completely dissolved. Then, mix and pipette the gel medium slowly into 
the gel cassette, trying not to leave any air bubbles. If there is any bubble, use a 
spacer to push it out. Then insert the 0.5 mm comb on the top of the gel. ¾ of the 
length of the comb teeth, not the whole teeth, should be in the gel medium, 
otherwise, it is hard to rinse the bottom of the wells. Still try not to produce any 
bubble. Wrap the gel cassette up and let it dry at room temperature for 2-3 hrs 
until use.  
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5. Load the gel cassette into the Vertical Gel Electrophoresis System 
(Bethesda Research Laboratories, Life Technologies, Inc. Gaithersburg). Fill the 
top tank and the bottom tank with 1x TBE buffer. Before loading the sample on 
the gel, pre-run the gel for at least 30 min. Rinse the wells and blow off the air 
bubbles at the bottom of the gel using a syringe right before loading. 
 
6. Load samples on the gel and run at 250 V for about 3-4 hr until the blue 
dye approaches the bottom.  
 
 
7. Take down the gel cassette and take off the binder clips. Use a spacer to 
separate the glass plates. The gel will stick to the big piece of plate that is wiped 
with Sigmacote. Cover the gel with a 3 mm Whatman paper and carefully peel 
the gel from the glass plate. Wrap the gel and paper with plastic film.  
 
8. Dry the gel in a vacuum gel dryer (Bio-Rad) at 80ºC for 2 hr and expose it 
to X-ray film and store at -80ºC overnight. 
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Appendix C 
 
In Vitro Translation Assay 
 
1. m7G capped mRNA preparation by in vitro transcription (mMESSAGE 
mMACHINE T7 kit, Ambion, Austin). 
 
a. Plasmids of 20 – 40 µg are digested with the restriction enzymes PvuII 
and Sac I in a 100 µl reaction mixture.  
b. Digestion products are separated on 1% agarose gel and the ~1.8 kb 
fragments are cut out under UV light and purified using Qiaquick Gel Extraction 
Kit (Qiagen).  
c. The volume of the gel-purified fragment is decreased to about 10 µl by 
vacuum concentration at 60ºC for about 25 min, and the fragments are used as 
DNA template in in vitro transcription reactions.  
d. Assemble the in vitro transcription reaction mixtures in 0.5 ml tubes as 
follows:  
 
Reagents Volume
DNA template 5 µl
2x NTP 10 µl
α- 32P- UTP 1 µl
10* buffer 2 µl
Enzyme Mix 2 µl
Total volume 20 µl
 
e. Gently flick to mix and spin to collect all at the bottom of the tubes. The 
reaction mixtures are incubated in heat block at 37ºC for 1 hr.  
f. Stop the reactions on ice and remove 2 µl of the products for yield 
quantitation.   
g. Add 1 µl of DNAout enzyme to degrade the DNA templates and incubate 
the mix at 37ºC for 15 min.  
h. Stop the reactions by adding 20 µl of RNAse-free water and 25 µl of 
lithium chloride precipitation solution, and mix thoroughly and store at -80ºC for at 
least 1 hr for RNA precipitation.  
 
2. Lithium chloride precipitation of mRNA. 
 
a. Centrifuge the chilled mRNA solutions at 4 °C for 30 min at maximum 
speed to pellet the RNAs.  
b. Carefully remove the supernatants. Wash the pellets twice with 250 µl of 
the mixture of DEPC-treated water and ethanol (30:70), and re-centrifuge to 
maximize removal of unincorporated nucleotides.  
c. Carefully remove the supernatants and dry the mRNA pellets for 2-5 min 
d. Resuspend the mRNAs in an appropriate volume of DEPC-H2O to make 1 
µg/ µl RNA concentration according to the yield calculated.  
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3. Quantitation of the mRNA yield by trace radiolabeling 
a. The in vitro transcription reaction products of 2 µl of are added into 198 µl 
of a carrier DNA solution (1 µg/µl of shredded salmon DNA, Ambion, Austin).  
b. Half of the carrier DNA solution passes through NucAway Spin Columns 
(Ambion, Austin) to remove free nucleotides. Briefly, tap NucAway Spin Columns 
on bench to collect all beads. Add 650 µl of DEPC-treated water into columns 
and vortex for one minute to get rid of any air bubbles. Columns are incubated at 
room temperature for 10 -15 min and chilled at 4ºC till use. Five minutes before 
use, columns are centrifuged at 800x g for 2 min at 4 ºC to remove the solution. 
After adding 100µl of the carrier DNA solution plus reaction product, columns are 
centrifuged again at 800x g for 2 min at 4 ºC to remove free nucleotide. The 
elution solution is used for scintillation counting.  
c. Scintillation counts the half of the carrier DNA solution and the elution 
solution from the NucAway Spin Column.  
d. Calculate the incorporation efficiency of α- 32P- UTP into mRNA which is 
the percentage determined by the following formula:  
 
  CPM of elution solution (without free radio-labeled nucleotides) 
 CPM of solution before elution (with free radio-labeled nucleotide) 
X 100%
e. Calculation of the yield of mRNA: 1% incorporation corresponds to 2 µg of 
mRNA.  
4. In vitro translation reaction 
 
a. Prepare mRNA solutions of 100, 20, 10, and 2 ng/µl by series dilution: 5 µl 
of the stock solution (1 µg/µl) into 45 µl DEPC-treated water to make 100 ng/ µl; 
10 µl of 100 ng/µl solution into 40 µl DEPC-treated water to make 20 ng/µl; 5 µl 
of 100 ng/µl solution into 45 µl water to make 10 ng/µl; and 5 µl of 20 ng/µl 
solution into 45 µl water to make 2 ng/µl.  
b. Assemble in vitro translation reaction mixtures in 0.5 tubes as follows:  
 
Reagents Volume 
Rabbit reticulocyte lysate                       22 µl 
Amino acids mix minus leucine             0.5 µl 
Amino acids mix minus Methionine       0.5 µl 
RNasin ribonuclease inhibitor (40 
U/µl)                                                 
1 µl 
mRNA  1 or 2 µl 
DEPC-treated water 7 or 6 µl  
Total volume 30 µl 
  
c. Incubate the reaction mix at 30ºC for 1 hr and stop the reaction on ice 
d. Measure the firefly luciferase activity using the Luciferase Assay System.  
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Appendix D  
 
Site-directed mutagenesis (QuikChange II Site-directed Mutagenesis Kit, 
Stratagene) 
 
1. Design primers. Primers must be longer than 27 nucleotides. Point 
mutation must be in the middle of the primer. Tm of primers calculated 
Stratagene QuickChange Tm Calculator must be higher than 75ºC for point 
mutation. Primers are better if they end with 1 or 2 G or C. 
  
2. Assemble the PCR reactions as follows:  
 
Reagents Volume or amount  
10X reaction buffer    5 µl 
Plasmid          10 to 50 ng 
Forward primer         125 ng 
Reverse primer          125 ng 
dNTP mixture            1 µl  
DEPC-treated water Up to 50 µl  
 
Then add 1 µl of PfuTurbo DNA polymerase. 
 
3.  PCR amplification.  
            The first cycle 
            Step:   1) 95°C for 30 sec 
                       2) 95 °C for 30 sec 
                       3) 55 °C for 1 min 
                       4) 68 °C for 1 min/kb of plasmid length 
Repeat step 2 to 4 12 times if it is a point mutation, 18 times if a multiple amino 
acid deletion or insertion.  
 
4. Following the temperature cycling, place the reaction on ice for 2 minutes.  
5.  Add 1 µl of the Dpn I restriction enzyme (10 U/µl) to the amplification 
reaction. Then incubate the reaction at 37 °C for 1 hr to digest the parental 
supercoiled dsDNA.  
6.  After the competent cells have melted on ice slowly, add 1 µl of the Dpn I 
treated DNA reaction product into 50 µl of the competent cells, gently flip the 
tube, and keep the transformation reaction on ice for 30 min. Then heatshock the 
transformation reaction at 42ºC in a waterbath for 45 sec, and place on ice for 2 
min.  
7. Add 500 µl of S.O.C medium ( Invitrogen) into the transformation reaction 
and incubate for exactly 1 hr at 37ºC at 250 rpm in shaker.  
8. Inoculate 100 to 200 µl of culture solution of Step 7 onto Agarose-LB plate 
containing 100ng/ml ampicillin and incubate at 37ºC overnight.  
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Appendix E 
 
The first strand of cDNA preparation (SuperScript III First-Strand Synthesis for 
RT-PCR).  
 
1. Prepare RNA/primer Mix as following  
 
Reagents Volume  
Total RNA (1µg/µl)                         1 µl 
50 ng/ µl random hexamers           1 µl  
10 mM dNTP                                  1 µl 
DEPC-ddH2O                                7 µl 
Total Volume 10 µl 
  
Incubate RNA/primer Mix at 65°C for 5 minutes.  
 
2. Prepare cDNA synthesis Mix as following 
 
Reagents Volume 
10X RT buffer                                2 µl 
25 mM MgCl2                                4 µl 
0.1 M DTT                                     2 µl 
RNaseOUT (40 U/µl)                     1 µl 
SuperScript III RT (200 U/µl)     1 µl 
Total Volume 10 µl 
 
3. Combine 10 µl cDNA syntheses Mix and RNA/primer Mix. 
4. Incubate the combined Mix at 25°C for 10 min, 50°C for 50 min, and then 
85°C for 5 min. Keep the reaction at 4°C. 
5. Add 1 µl of RNAse H into the reaction and incubate for 20 min. 
6. Store cDNA at -20°C till use. 
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Appendix F 
 
Online programs  
 
1. Translate Tool: a tool which allows the translation of a nucleotide (DNA/RNA) 
sequence to a protein sequence. 
http://www.expasy.org/tools/dna.html
 
2. RestrictionMapper: maps sites for restriction enzymes in DNA sequences. 
http://www.restrictionmapper.org/
 
3. Oligonucleotide Properties Calculator: calculates Tm and checks self-
complementarity.  
http://www.basic.northwestern.edu/biotools/oligocalc.html
 
4. RNA mfold: predicts RNA secondary structure. 
http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1.cgi
 
5. Stratagene Quikchange Primer Tm Calculator: calculates the Tm of oligos 
specially for QuikChange® Site-Directed Mutagenesis kits  
http://www.stratagene.com/QPCR/tmCalc.aspx
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